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CHARACTERISATION OF WNT SIGNALLING PATHWAY IN  
RHABDOMYOSARCOMA 
 
Dr Srinivas Rao Annavarapu 
 
Introduction 
 
Rhabdomyosarcoma (RMS) remains one of the most challenging tumours in 
paediatric oncology, accounting for around 5% of all malignant paediatric tumours. 
Of the two major subtypes of RMS, embryonal and alveolar, the latter portends a 
poorer clinical outcome. Canonical Wnt signalling pathway is an important 
evolutionarily conserved signalling pathway that is required for muscle development 
and embryonal somite patterning. β-Catenin is a potent nuclear transcriptional 
activator and is the central effector of the canonical Wnt signalling pathway. 
Interestingly, constitutional activation of Wnt signalling also promotes tissue 
invasion and metastasis in various tumours.  
 
Aims 
 
This study aims to characterise the canonical Wnt/β-catenin signalling in paediatric 
RMS to assess its functional relevance to the tumourigenesis of RMS and to 
investigate if modulation of this pathway could provide a therapeutic target for RMS.  
 
Results 
 
When we evaluated the immunohistochemical expression of β-catenin in the 
paraffin-embedded tissues derived from 44 RMS patients, we found positive 
expression in 26 cases. There was positive expression of β-catenin in the cytoplasm 
or the cell membrane of alveolar (9/14) and embryonal RMS (15/30); nuclear 
staining was only seen in two embryonal RMS cases. Next, we assessed β-catenin 
expression by immunoblot analysis in four RMS cell lines – RD and RD18 
(embryonal); Rh4 and Rh30 (alveolar). We were able to demonstrate expression of 
major canonical Wnt proteins in all cell lines that included: β-catenin, glycogen 
synthase kinase-3β, disheveled, axin-1, naked and LRP-6. To assess the functional 
significance of these proteins, we incubated the RMS cell lines with human 
recombinant Wnt3a to stimulate the Wnt signalling pathway. Thereafter, by using 
cellular fractionation and immunofluorescence experiments, we demonstrated 
change in the phosphorylation status of β-catenin, stabilisation of its active form and 
its nuclear translocation. By employing a TOP/FOP flash reporter gene assay, we 
showed a T-cell factor/lymphoid-enhancing factor (TCF/LEF)-mediated 
transactivation. In addition, we found a significant decrease in the proliferation rate 
of the alveolar RMS cells after Wnt3a stimulation. This decrease in proliferation rate 
was thought to be due to the concomitant activation of myodifferentiation as seen by 
the immunoblot expression of myogenin, MyoD1 and myf5. Our data indicates that 
the major regulatory proteins of the canonical Wnt/β-catenin signalling are expressed 
in RMS and that functional activation of this pathway, at least in a subset of RMS, 
may represent a novel therapeutic target.  
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CHAPTER 1 – INTRODUCTION 
 
1.1 Soft tissue tumours 
Sarcomas are a heterogeneous group of malignancies arising from 
mesodermal structures and show a myriad range of differentiation. A 
subset of these, are called soft tissue sarcomas (STSs) that commonly 
arise from the connective tissues of the body that includes muscle, nerve, 
fat and blood vessels [1].  
Most soft tissue tumours are benign in behaviour with good 
prognosis after complete surgical excision. Malignant soft tissue 
tumours are rare (<1% of all malignant tumours) but may present with 
diagnostic therapeutic challenges since greater than fifty histological 
subtypes are recognized, each having their own distinctive 
clinicopathological and therapeutic attributes. Histologic classification is 
based upon morphologic demonstration of a specific line of 
differentiation. With the advances in genetics, our understanding of the 
biological behaviour of the soft tissue tumours has increased remarkably 
over the past two decades as ancillary diagnostic techniques like 
immunohistochemistry, fluorescent in-situ hybridisation (FISH) and 
electron microscopy has become routine. The STTs are stratified 
according to their lineage of origin by taking into account their 
morphologic features and novel genetic findings [2].  
 21 
 STTs occur in both children and adults, however the incidence is 
much higher in children, where it accounts for around 20% of all 
malignancies as compared to adults where it makes up for around 1% of 
cases [3]. The annual incidence of paediatric tumours in the UK is 
around 1700 with about 257 deaths every year [4]. Therefore, continued 
research towards identifying novel effective management strategies is 
crucial. 
1.2 Paediatric Soft tissue tumours 
STSs embrace features of various differentiation stages seen during the 
maturation of mesenchymal stem cells to mature mesodermal structures 
such as skeletal muscle (rhabdomyosarcoma), smooth muscle 
(leiomyosarcoma), Schwann cells (malignant peripheral nerve sheath 
tumors), fibrous tissue (fibrosarcoma), adipose tissue (liposarcoma) and 
blood vessels (angiosarcoma, hemangiopericytoma) [1].  
In a subset of STSs, the definitive origin remains unclear (e.g., 
synovial sarcoma, malignant fibrous histiocytoma, alveolar soft part 
sarcoma). In some cases, the STSs show very primitive mesenchymal 
phenotype similar to the mesenchymal stem cells (Ewing sarcoma, 
undifferentiated sarcomas) [1].  
In 2013, the World Health Organization (WHO) classified soft tissue 
sarcomas on the basis of their putative phenotype (tissue they 
resemble/likely cell of origin) and biological behavior [5]. In some 
 22 
cases, the origin of the sarcoma is unclear and these are believed to have 
mesenchymal stem cell phenotype. Thus, the soft tissue sarcomas 
encompass a heterogeneous group of entities, which show diverse 
phenotypes and have variable biological behaviour depending upon the 
underlying genetic abnormality.  Sarcomas are graded histologically in 
benign, borderline and malignant tumours using morphological criteria 
like tumour differentiation score, mitotic count and tumour necrosis 
(French Federation of Cancer Centers Sarcoma Group system) [6]. This 
allows predicting the clinical behaviour of the tumour and helps to 
correlate with its underlying genetic abnormality. The current study 
focusses on the molecular pathology of the most common paediatric 
STS – rhabdomyosarcoma. 
1.3 Rhabdomyosarcoma 
Rhabdomyosarcoma (RMS), accounts for around 4-5% of paediatric 
malignancies and is the most common soft-tissue sarcoma of childhood 
and adolescence [7, 8]. The incidence of RMS in the UK is around 60 
cases per annum [9], whereas in the United States, a diagnosis of RMS is 
made in around 350 children and adolescents [10, 11]. Most cases are 
sporadic in nature, although familial cases (around 5%) may be 
associated with germ line mutation of Tumour protein 53 (TP53) in Li-
Fraumeni syndrome [12] and with germ line mutations in NF-1 in 
Neurofibromatosis [13]. It is reported to be more common in males than 
 23 
in females [7]. RMS shows a bimodal age distribution depending upon 
its subtype, though most children are less than 10 years of age [7]. 
1.4 Classification of RMS 
Histogenetically, RMS as a group demonstrates skeletal muscle 
differentiation but histo-morphologically they can show diverse array of 
patterns.  
The WHO classification (2013) recognizes the following RMS 
subtypes: embryonal, alveolar, spindle cell/sclerosing and pleomorphic 
[8, 14, 15]. Of these, the alveolar and the embryonal RMS, are the two 
major clinicopathological subtypes that need to be separated as they 
have important prognostic and therapeutic implications.  
Embryonal RMS (ERMS) is more common subtype (70% of 
cases) and has a better prognosis. On the other hand, the alveolar RMS 
(ARMS) subtype (30% of cases) has a more aggressive course and has 
poorer prognosis with limited therapeutic options [9, 16, 17].  
The International Classification of Rhabdomyosarcoma stratifies 
RMS subtypes into prognostic categories (See Table 1.1) where botryoid 
and spindle-cell RMS subtypes are considered in the superior-risk group 
category. Embryonal RMS and alveolar RMS fall into the intermediate-
risk and the unfavorable-risk group respectively [7, 15, 18, 19]  
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Table 1.1 - International Classification of Rhabdomyosarcoma [14] 
        Superior Prognosis Botryoid RMS 
Spindle cell RMS 
Intermediate Prognosis Embryonal RMS 
         Poor Prognosis Alveolar RMS 
Undifferentiated RMS 
         Unknown Prognosis             RMS with rhabdoid features 
 
In contrast to embryonal RMS which presents in early childhood, the 
alveolar RMS occurs more frequently in older children, has a more 
aggressive behaviour, portends a poorer prognosis and more commonly 
present with metastasis to bone marrow [20].  
Botryoid and spindle cell RMS subtypes have very characteristic 
presentations, have very good prognosis and most likely represent 
variants of embryonal RMS [7].  
As a group, both ERMS and ARMS are diagnosed by nuclear 
immunostaining for the myogenic nuclear transcription factors –
Myogenin and MyoD1 and structural proteins markers like desmin, 
myosin heavy chain, myoglobin and skeletal α-actin [21-24] (See 
Fig1.1).  
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Figure 1.1- Immunohistochemical panel for the diagnosis of RMS 
Although it is tempting to conclude that these markers indicate a skeletal 
muscle differentiation from mesenchymal stem cells, non-myogenic 
lineage of the tumor cells has also been demonstrated [25]. RMS most 
commonly arises from skeletal muscle but can also be seen developing 
from non-myogenic sources like salivary glands, biliary/genitourinary 
tract and para-meninges [24, 25]. However, from a diagnostic 
standpoint, immunohistochemical demonstration of nuclear MyoD1 and 
Myogenin with/without cytoplasmic desmin is central to establish a 
diagnosis of RMS [22, 26] (Fig 1.1). Reticulin stain is useful as an 
adjunct to differentiate ARMS from ERMS; whereas the distribution is 
peri-cellular in ERMS, reticulin outlines cellular aggregates of the 
D33
MyoD1Myogenin
Immunohistochemistry
Desmin positive
Myo D1 positive (Nuclear)
Myogenin positive (Nuclear)
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tumour cells in ARMS [27]. Recently AP2β and β-catenin have been 
shown to be potent markers of fusion-positive ARMS [28]. 
1.5 Embryonal RMS 
ERMS is a malignant soft tissue tumour that shows differentiation 
towards skeletal muscle differentiation of up to 10-12 weeks in 
embryonic development. They are thought to be arising from primitive 
mesenchymal stem cells showing variable myogenic differentiation [29]. 
Most children are less than 5 years old. They can occur at any site 
though their favored locations are genitourinary tract, where they can 
present as urinary obstruction or in the head/neck region presenting as 
retro-orbital mass. They also can occur as visceral masses (especially 
biliary), prostatic lesions or limbs [7, 8]. 
The pathology of ERMS recapitulates embryonic myogenesis and 
shows primitive mesenchymal cells set in a hypocellular myxoid 
background with hyperchromatic nuclei and variable amount of 
amphophilic cytoplasm [29]. Focally, the tumour shows elongated, 
eosinophilic strap cells with cross-striations – rhabdomyoblasts, 
providing histological evidence of skeletal muscle differentiation [29]. 
Immunohistochemistry is crucial to ascertain the myogenic lineage – 
nuclear MyoD1 and Myogenin with cytoplasmic Desmin [26]. 
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The botryoid subtype presents clinically with distinctive grape-like 
polyps projecting from mucosal surfaces. The sub-epithelial regions 
show distinctive zones of cellular condensation, the so-called the 
Cambium layer (See Fig 1.2). The tumour cells show nuclear staining 
for MyoD1 and Myogenin with variable cytoplasmic positivity for 
Desmin [7].  
 
 
Figure 1.2 - Histology of botryoid type RMS showing characteristic 
sub-epithelial Cambium layer. 
 
The spindle cell subtype presents mostly as a paratesticular or a 
head/neck mass with dense fascicles of spindle cells forming a whorled/ 
herring-bone pattern. They show minimal cellular pleomorphism with 
little or no nuclear atypia and low mitoses [30]. Focally, 
rhabdomyoblasts are present. The tumour cells also show nuclear 
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staining for MyoD1 and Myogenin. Spindle cell RMS and botryoid 
RMS may also co-exist [29]. 
Anaplastic variant of ERMS is characterised by tumour cells having 
enlarged, hyperchromatic nuclei and multipolar mitoses [29]. Analogous 
to that defined for Wilms’ tumour, anaplasia in RMS can be divided into 
focal and diffuse. Diffuse anaplasia when occurring in children with 
intermediate-risk embryonal rhabdomyosarcoma may have a poor 
prognosis [31]. Similar to the other ERMS subtypes, the tumour cells 
show nuclear staining for MyoD1 and Myogenin. Spindle cell RMS with 
anaplasia can resemble pleomorphic RMS seen in adults, but this is 
extremely rare [29]. Prognostically, the low-risk patients have a 5-year 
survival rate of 80-90%, whereas patients in the intermediate and the 
high-risk groups have 4-year survival rates of 70% and 23% respectively 
[32-34]. 
1.6 Alveolar RMS 
Alveolar RMS is an aggressive soft tissue tumour with myogenic 
differentiation that is characterised by small round blue cells. Most 
tumours show an alveolar pattern but solid and anaplastic variants are 
also known [29]. In contrast to ERMS, these tumours mostly arise from 
the extremities, perineum and the sinonasal region as painless soft tissue 
mass. Another distinguishing feature is the wider age range of 
presentation as it is relatively more common in older children and 
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adolescents. The tumour grows rapidly as an expansive mass that has the 
propensity to invade adjacent structures and metastasize early to bone 
marrow, lymph nodes and lungs [29]. 
Histologically, there are two main types of patterns – classic alveolar 
and solid variants. The alveolar pattern shows delicate fibrovascular 
septae lined by small round blue cells, which have a tendency for central 
dyscohesion (See Fig 1.3). There is scant evidence of myogenesis, 
although some multinucleated giant cells analogous to embryonic fused 
myoblasts may be seen [7, 29]. 
 
 
Figure 1.3 - Histology of classic alveolar RMS showing small round 
blue cells with central dyscohesion. 
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1.7 Genetics of RMS 
 
Alveolar RMS shows distinctive t(2;13)(q35;q14) and t(1;13)(q36;q14) 
translocations, involving the PAX3–FOXO1(Forkhead box protein O1; 
formerly known as Forkhead receptor/FKHR) and PAX7–FOXO1 
fusion genes, respectively [35, 36]. Pax7 (chromosome 1) and Pax3 
(chromosome 2) genes belong to the Pax family of transcription factors 
that contain a C-terminal transactivation domain and an N-terminal 
DNA-binding domain composed of homeobox motifs and paired box. 
FOXO1 also contains C-terminal transactivation domain and an N-
terminal DNA-binding site [35, 36]. The breakpoint in the reciprocal 
translocation occurs at the site of intron 7 for Pax genes and intron 1 for 
FOXO1; after fusion, this encodes a chimeric proteins Pax3–FOXO1 
and Pax7–FOXO1, which contains 5′ DNA-binding domain of Pax and 
the 3′ transactivation domain of FOXO1 [24,] (See Fig. 1.4). 
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Figure 1.4 - Schematic diagram showing the characteristic Pax3/7-
FOXO1 fusion gene found in ARMS. PD = Pairing domain; HD = 
Homeodomain; TAD = transactivation domain. 
 
The mechanisms of how this fusion gene product, detectable by 
fluorescent in situ hybridization (FISH), causes dysregulation of 
differentiation of myogenic progenitor stem cells, is not fully 
understood. PAX3-FOXO1-positive ARMS also frequently show gene 
amplification of other critical genes including MDM2, CDK4, MYC-N 
and GLI proto-oncogenes. Some ARMS show alternate fusion 
transcripts to FOXO1 by incorporating NCOA1, NCOA2 or AFX. 
Rarely, PAX gene may be replaced by FGFR [20].  
Pax3/7-FOXO1
FOXO1
Pax3/7
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Some tumours with otherwise typical ARMS histology are negative 
for PAX-FOXO1 defects but have prognosis similar to ERMS [37]. 
Around one-fifth of ARMS tumors do not express PAX-FOXO1 
rearrangement; these “fusion negative” ARMS cases have clinical 
outcomes comparable to those with ERMS [38, 39]. Since the prognosis 
of translocation-negative ARMS is largely similar to that of ERMS, 
Lupo (2015) recommends that these two entities should be clubbed in 
future epidemiologic investigations as they may represent the same 
entity [40].  
Unlike ARMS, ERMS show a diverse range of non-specific genetic 
abnormalities, possibly related to the morphological variations in 
myodifferentiation in ERMS [41]. However, epigenetic changes such as 
loss of heterozygosity (LOH) for parts of Chromosome 11p15.5 
alterations are consistently seen [42]. This has been postulated primarily 
to be a consequence of uniparental disomy [43]. 
1.8 Molecular biology of RMS 
Pax3 is physiologically required in muscle development but transfection 
of Pax3 in cultured fibroblasts does not transform them. However, when 
co-transfected with Pax3–FOXO1, the fibroblasts were transformed [44, 
45]. Similarly, transfecting ERMS cell line with Pax3–FOXO1 resulted 
in increased cell proliferation and tumor growth [36].  
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The underpinning mechanisms of how Pax–FOXO1 effects 
oncogenesis are not completely understood. However, it has been shown 
that Pax–FOXO1 chimeric proteins is capable of a 100-fold increase in 
the transcriptional activity as compared wild-type Pax3/7. Thus, the 
dosage of the Pax3–FOXO1/Pax7–FOXO1 chimeric proteins is critical 
[46, 47]. There are subtle differences in the Pax3–FOXO1 and Pax7–
FOXO1 translocations, whereas the former results in a hectic increase in 
gene transcription [48], overexpression of the latter causes gene 
amplification [49]. In addition, Pax3–FOXO1 has a significantly longer 
half-life as compared to Pax3 [50]. Pax–FOXO1 proteins also induces 
expression of B-cell lymphoma-extra large (BCL-XL) gene, an anti-
apoptotic gene [51, 52]. In addition, Pax–FOXO1 suppresses terminal 
muscle differentiation [53].  
On microarray analysis, Pax–FOXO1 proteins shows an explicit 
molecular signature of ARMS consistent with its action of promoting 
proliferation and suppressing terminal muscle differentiation [41]. One 
such target is fibroblast growth factor receptor-4 (FGFR4) that is known 
to promote tumour growth and survival [54]. Pax3 also activates FGFR 
signalling, which promotes growth of myoblasts [55]. It is thought that 
Pax3–FOXO1 promotes cell proliferation through the FGFR4 pathway. 
Insulin-like growth factor-1 receptor (IGF1R) is another downstream 
target of Pax3–FOXO1 that may promote myoblast growth [56]. Since 
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both FGFR and IGF1R promote differentiation of myoblasts, it is 
plausible that Pax3–FOXO1 signals through these receptors keep the 
RMS cells in a state of proliferation whilst retaining some differentiation 
markers [24].  
Hepatocyte Growth Factor (HGF)/c-mesenchymal-epithelial 
transition (c-MET) receptor is another important growth-promoting gene 
that is overexpressed in fusion-positive ARMS and appears to be a direct 
target of Pax3–FOXO1 [57, 58]. c-Met receptor signalling activates the 
quiescent myogenic progenitor cells to proliferate after muscular 
damage [24, 59]. c-Met appears to regulate dichotomy of cell fates in 
ARMS. Tumours with decreased c-Met expression show a more 
differentiated phenotype (See Fig 1.5). It has recently been shown that 
microRNA-206 (miR-206) induces ARMS differentiation by targeting c-
Met [24, 60]. 
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Fig 1.5 - Schematic diagram showing dichotomy of fates effected by c-
Met, a downstream target of Pax3/7. [61]. 
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Pax–FOXO1 inhibits muscle differentiation by effecting strong 
epigenetic inhibition of MyoD transcriptional activity [24]. It inhibits 
MyoD (and its downstream Myogenin) by preventing chromatin 
remodeling by reducing acetylation of histone H4 and RNA 
polymerase II [62]. This may maintain RMS cells in a less differentiated 
state since Myogenin is required for myogenic differentiation [24]. 
MyoD also binds with histone acetyltransferases (e.g. p300/CREB-
binding protein) and histone deacetylases to regulate expression of 
myogenic genes. Myostatin, part of the transforming growth factor-β 
(TGF-β) superfamily, is another mediator of Pax–FOXO1 signals that 
repress myogenic differentiation by acting through activin receptor 
type IIb to activate Smad proteins [24]. 
Recent studies have shown that Wnt signalling pathway, crucial in 
embryonal development and myogenesis, may be linked to 
rhabdomyosarcoma [63, 64]. Moreover, Wnt also regulates the 
expression of MyoD and Myogenin and may be important in the 
regulation of myogenic differentiation [65, 66].  
The following section examines the Wnt signalling pathway and 
highlights how this pathway could be important in the pathogenesis of 
RMS. 
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1.9 Wnt Signalling Pathway 
Wnt signalling pathway is conserved through the evolution across 
invertebrates and vertebrates and is key in regulating key cellular 
interactions during embryonic development [67, 68]. There are three 
recognised arms of Wnt signalling pathway: canonical Wnt pathway, 
Wnt/calcium pathway and the planar cell polarity pathway [68]. As a 
group, the Wnt pathways become active when an appropriate ligand 
binds to a Frizzled family of receptors (Fzd), which activates 
downstream signalling and relays the biological signal to the nuclear 
machinery. The canonical Wnt pathway (main focus of the study) 
regulates gene transcription of the downstream targets; the non-
canonical planar cell polarity pathway regulates the cell cytoskeleton 
and the Wnt/calcium pathway regulates intracellular levels of calcium 
[69]. Wnt signalling pathways may act in a paracrine or autocrine 
manner [68]. 
1.9.1 Regulation of Wnt signalling 
β-catenin, the key player of the canonical Wnt signalling pathway, is a 
nuclear transcription factor, that executes the Wnt functions in cellular 
interactions during development [67]. Within the cell, β-catenin exists in 
two major pools – bound to the Cadherins as a part of the adherens 
junction [70] and as free β-catenin that is actively degraded in the 
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cytoplasm and the amount of free intracellular β-catenin is tightly 
regulated [68].  
In brief, when the Wnt pathway is switched off, β-catenin is 
retained in the cytoplasm by a degradation complex containing CK1α, 
GSK3β, Axin and APC protein [68]. This complex sequentially 
phosphorylates β-catenin (inactive form) at various sites that causes 
ubiquitination of β-catenin and subsequent degradation by the 
proteasome [67, 69] (See Fig 1.6).  
 
Figure 1.6 - Schematic diagram of Wnt signalling pathway. Under basal 
conditions β-catenin is sequestered by the degradation complex and 
marked for proteasome destruction. In the presence of Wnt ligand, 
Disheveled rescues β-catenin from destruction. Free β-catenin 
translocates to the nucleus and activates Wnt target genes. 
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In the active state, the Frizzled receptors interact with Wnt ligands 
and the Low-density lipoprotein receptor/LRP-group of co-receptors on 
the cell surface. This binding triggers a relay of cytosolic signals that 
activates a downstream protein Dishevelled (Dvl) that consequently 
destabilizes the degradation assembly by inhibiting GSK3β via 
phosphorylation and rescues β-catenin from proteosomal degradation 
[68]. The unphosphorylated β-catenin (active form) can now translocate 
to the nuclear and form a complex with T-cell factor/lymphoid 
enhancer-binding factor (TCF/LEF) to activate downstream target genes 
like Axin-2, c-Myc, c-Jun, Cyclin D1, Slug, Matrix metalloproteinase-7 
(MMP-7) etc. that promote cellular proliferation, migration, invasion, 
survival and metastasis [68]. In addition, Wnt pathway may cross talk 
with other signalling pathways to modulate cellular responses to various 
stimuli [69].  
1.9.2 Wnt signalling in normal development 
Developmental studies in Xenopus embryos, Drosophila and C. elegans 
have shed valuable information on the mechanisms operative in Wnt 
signalling pathway [68]. Wnt signalling is important in the regulation of 
body axis patterning, cell fate specification, cell proliferation and cell 
migration [71]. It is required for various developmental processes 
including stem cell renewal [71-73]; haematopoiesis [74, 75]; 
development of hair follicle [76]; testicular development and 
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spermatogenesis [77, 78], proliferation of gastric [79, 80] and intestinal 
epithelium; craniofacial development [81], bone development [82, 83]; 
fracture healing [84] and development of teeth [85, 86]. The differential 
gradients created by the Wnt proteins in relation to Sonic hedgehog 
(Shh), Notch and Bone morphogenetic protein (BMP) signalling is 
crucial in axis patterning as shown in Fig 1.7 [87]. 
 
Figure 1.7 – Role of Wnt signalling in somite patterning and 
myogenesis. Role and Function of Wnts in the Regulation of 
Myogenesis: When Wnt Meets Myostatin in "Skeletal Muscle [87]  
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Previous and recent studies confirm that Wnt signalling is crucial 
in myogenesis [83, 87-91]. In particular, dysregulation of Wnt pathway 
can lead to a plethora of skeletal developmental anomalies [69]. 
1.9.3 Wnt signalling in Cancer 
Deregulation of Wnt signalling, caused by germ line and/or somatic 
mutations in Wnt pathway components, causes many types of human 
tumours [93-95]) (See Fig 1.8).  
Activating β-catenin mutations, that alter specific β-catenin 
residues required for GSK3β phosphorylation and its subsequent 
degradation, have been reported in human colon cancer [96] and 
melanoma [97]. Since mutated β-catenin may constitutively activate 
downstream target genes, many of which may promote cellular 
proliferation, migration, invasion, survival and metastasis, it is easy to 
see how dysregulation of Wnt/b-catenin signalling can facilitate 
tumourigenesis in various organ systems where Wnt signalling is active 
[68, 69, 98].  
Deregulation of Wnt pathway causes malignancies in a wide 
variety of organs such as colon [99, 100], skin [101, 102], liver [103, 
104], lung [105], pancreas [106], thyroid [107-109], endometrium [110, 
111], prostate [113] and brain [113-114]. Mutations in other Wnt 
proteins such as APC were identified in colorectal carcinomas [115]; 
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Axin1 gene mutations have been reported in hepatocellular carcinomas 
[116]. 
 
Figure 1.8 – Dysregulation of Wnt signalling (red arrow) results in 
persistent renewal and abnormal expansion of the stem cells that can 
cause colorectal cancer [93]. 
 
1.10 RMS and Wnt – Is it relevant? 
There are several compelling arguments in favour of why Wnt signalling 
pathway could be relevant and important in rhabdomyosarcoma. 
1. Wnt signalling is an important developmental pathway required 
for somite patterning and limb development (as described in 
section 1.6). The Wnt signalling pathway is also actively involved 
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in myogenesis [117-119] and embryonic somite patterning [120, 
121]. Petropoulos (2002) showed that β-catenin was essential and 
sufficient for skeletal myogenesis in P19 cell lines. They used P19 
cell lines with stably expressed Wnt3a or with mutated β-catenin 
and found evidence of myogenesis in the test P19 cell lines as 
compared to the control cells. Prior to MyoD expression, other 
myogenic markers Pax3, Gli2, Mox1, and Six1 were also 
expressed upon Wnt3a/β-catenin-induced differentiation [122]. 
2. Diagnosis of RMS is based on the demonstration of 
immunohistochemical expression of nuclear transcription factors, 
Myogenin and MyoD1 [26], both of which are capable of 
inducing myogenic differentiation [91] and appear to be 
downstream of canonical Wnt signalling pathway [123] (See Fig 
1.9).  
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Figure 1.9 – Myogenic differentiation markers MyoD and Myf5 appear 
to be downstream of canonical Wnt signalling pathway and are 
modulated by BMP via SMAD [123]. 
 
3. ARMS show distinctive translocations, involving the PAX3–
FOXO1 and PAX7–FOXO1 fusion genes [36]. Interestingly, Pax3 
and Pax7 genes are required for myogenesis and have been 
demonstrated to be downstream of Wnt signalling in muscle 
development [118]. Furthermore, it has been shown that Wnt 
pathway cooperates with both Pax3 and Pax7 genes to promote 
myotubule formation [124].  
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4. Wnt pathway also co-operates closely with the other embryonal 
pathways like Shh [125] and Notch [126] during skeletal 
development. Further, there is evidence that Wnt pathway may 
crosstalk with Shh and TGF-β pathways in the process of 
epithelial-to-mesenchymal transition (EMT), which is important 
in embryonic development, wound healing, and tumour formation 
[127].  
 
Taken together, it appears that there could be important links between 
the Wnt signalling pathway and rhabdomyosarcoma that warrants 
further investigation. Hence, I found it justifiable to ask the question if 
Wnt signalling could be relevant in the pathogenesis of RMS. 
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1.11 Aims  
 
Given its role in myogenesis and tumourigenesis, the main purpose of 
the project is to characterise Wnt signalling pathway in RMS with an 
aim to elucidate whether canonical Wnt pathway plays any role in the 
tumourigenesis of RMS and whether manipulation of this pathway could 
provide any therapeutic target for RMS. 
• To verify the expression of the central Wnt regulator β-catenin in 
tissue samples of RMS patients to establish clinical relevance of 
Wnt signalling pathway to RMS. 
• To investigate whether the major Wnt pathway proteins and their 
downstream targets are expressed in the RMS cell lines in-vitro.  
• To investigate whether Wnt signalling pathway is functionally 
active in RMS cell lines. 
• To investigate whether modulation of Wnt signalling pathway in 
RMS cell lines could have any therapeutic implications. 
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1.12 Objectives 
 
• To assess the expressional analysis of β-catenin by the means of a 
Tissue Microarray (TMA) on archival clinical RMS tissue 
samples from two major Children’s hospitals.  
• To assess the expressional analysis of Wnt components (including 
beta-catenin, components of the degradation complex, Wnt co-
receptors and downstream targets) in the RMS cell lines by 
Western blot analysis.  
• To assess the phosphorylation status of β-catenin after Wnt3a 
activation in-vitro in the RMS cell lines using different β-catenin 
phospho-antibodies. 
• To assess the localisation of β-catenin in cellular compartments 
(cell membrane, cytoplasm and nucleus) after Wnt3a activation 
in-vitro in RMS cell lines by confocal immunofluorescence 
microscopy and immunoblot assays using nuclear/cytoplasmic 
cell extracts. 
• To assess functional status of β-catenin/LEF-TCF interaction after 
Wnt3a activation in-vitro by Report gene assay (TOP/FOP flash 
using Gaussia Luciferase assay) and by immunoblot expression 
analysis of the downstream targets. 
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• To assess the effect of Wnt3a activation (in-vitro) on the 
proliferation activity of RMS cell lines using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
proliferation assay. 
• To assess the effect of Wnt3a activation (in-vitro) on apoptosis in 
RMS cell lines using Caspase 3/7 assay. 
• To assess the effect of Wnt3a activation on the morphology of 
RMS cells lines using confocal immunofluorescence microscopy.  
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CHAPTER 2 – REVIEW OF LITERATURE 
 
2.1 What is Wnt signalling pathway? 
Wnt signalling is a remarkably conserved pathway across invertebrates 
and vertebrates that plays a vital role in the skeletal development [68]. 
The pathway comprises three arms, canonical Wnt/β-catenin pathway, 
the planar cell polarity pathway and the Wnt/Ca2+ pathway. These 
pathways are involved in intracellular signalling following Wnt-ligand 
interactions with cell surface receptors [68, 69, 128]. 
Canonical Wnt signalling pathway comprises a family of secreted 
glycolipoproteins that regulate cell fate determination, cell polarity and 
cell proliferation during embryonic development [113]. It cross talks 
with other embryonal pathways like Shh and Notch in formation of the 
body axis, somite patterning and limb development [64]. Since the Wnt 
pathway directs many of the steps related to tissue homeostasis, 
dysregulation of this pathway results in congenital skeletal defects and 
tumours [69]. Canonical Wnt pathway regulates the amount of 
intracellular β-catenin, a powerful nuclear transcriptional activator that 
controls the genes expression of downstream targets [128, 129] (See Fig 
2.1).  
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Figure 2.1 - β-catenin exists within the cell in two major pools – as a 
part of the adherens junction in association with Cadherin and other 
catenins, and as a that is tightly regulated nuclear transcription factor, 
central to the canonical Wnt signalling pathway [130]. 
 
Historically, Wnt signalling was first described for its role in 
cancer and its role in embryonic development was discovered later [68]. 
In 1982, Roel Nusse and Harold Varmus infected mice models with 
oncogenic retroviruses in an attempt to mutate mouse genes to see which 
transformed genes could cause mammary tumours. A new mouse proto-
oncogene was identified that was named int1 (integration 1) [68, 131]. 
Int1 was found to be highly conserved across vertebrates and 
invertebrates including humans and Drosophila. It was soon realized 
however that the int1 gene described in Drosophila had a homologous 
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gene in Wingless (Wg) family of genes [132] that had been 
characterized previously in Drosophila [133]. Wg was implicated in 
segment polarity during the formation of body axis during embryonic 
development [68, 134]. Hence, the int and the Wg family was renamed 
as the Wnt family reflecting "Wingless-related integration site" [134].  
2.1.1 Activation of the canonical Wnt signalling pathway  
Wnt/β-catenin signalling pathway is activated when Wnt ligands, a 
family of secreted glycolipoproteins, bind to the transmembrane Frizzled 
group of receptors [69]. There are 19 different members in the humans 
[128]. Wnt ligands are actively secreted and they interact with two co-
receptors on the cell surface – seven transmembrane Frizzled (Fzd) 
receptors that directly bind with the Wnt ligand through cysteine-rich 
domains at N-terminus [113, 135] and single-pass transmembrane low-
density lipoprotein receptor-related proteins 5/6 (LRP-5/6) [136, 137] 
(See fig 2.2). 
The Fzd receptors once activated by Wnt ligand binding, relay 
signals intracellularly as they are coupled with heterotrimeric G proteins 
[135]. LRP-5/6 is an important co-receptor that can modulate the Fzd-
Wnt interaction by the binding to extracellular inhibitors WISE and 
Dickkopf (Dkk) [137]. Several versions of DKK genes exist in humans, 
however, DKK1 is the most important inhibitor of the Wnt/β-catenin 
signalling [138]. DKK1 binds with LRP-5/6 and Kremen that causes 
 53 
internalization of LRP-5/6, consequently inhibiting Wnt/β-catenin 
signalling. The type of internalization of LRP-5/6 determines whether 
the Wnt pathway will be activated or inhibited. DKK-induced-Clathrin 
mediated internalization, causes Wnt pathway inhibition whereas LRP-
5/6 internalization via Caveolin activates Wnt/β-catenin signalling [139, 
140].  
On the other hand, Wise and Sclerostin (SOST) proteins interfere 
with the association between Wnt ligands and LRP5/6 [141]. Inhibitors 
like Cerberus (CER) and FrzB-1 sequester Wnt ligands and prevent their 
interaction with the Fzd receptor [142]. Wnt inhibitory factor (WIF) 
directly binds to the Wnt ligands and prevent their availability [128]. 
Secreted Frizzled related proteins (sFRPs) compete with Fzd receptors 
as structurally they share homologous cysteine rich domains [143]. Shisa 
protein inhibits maturation of the Fzd receptors and prevents them from 
reaching the cell surface and isolating them in the endoplasmic 
reticulum [144]. Recently, it has been shown that post-translational fatty 
acylation is a key step in Wnt secretion and receptor recognition [129]. 
When Wnt ligands interact with Fzd and LRP5/6, the receptors 
coupled to G proteins on the inner side of the plasma membrane 
transduce signal to Dishevelled (Dvl) and Axin, and bind with β-catenin 
through their DIX domain [145]. Protease-activeated receptor-1 (PAR1) 
protein phosphorylates Dvl which then binds to Fzd intracellularly and 
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rescues β-catenin from degradation by recruiting glycogen synthase 
kinase binding protein (GBP)/Frequently rearranged in advanced T-cell 
lymphoma-1 (FRAT-1) [142] (See Fig 2.2).  
 
  
Figure. 2.2 – Schematic diagram depicting regulation of Fzl-LRP5/6, 
APC-Axin-GSK3 complex and TCF/LEF repressors and activators 
during Wnt off and Wnt on stages. In the Wnt off state, TCF/LEF 
transcription is blocked is by Groucho and histone deacetylase (HDAC). 
β-catenin accumulates in the cytoplasm and translocates to the nucleus 
once it is rescued by the action of Dvl upon Wnt ligand binding 
association with Fzl and LRP5/6. β-catenin displaces the TCF/LEF 
repressors and with the help of TCF/LEF activators, swtiches on the Wnt 
target gene transcription. 
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serine/threonine kinases GSK3β and Casein Kinase 1α (CK1α). The 
degradation complex captures free β-catenin, sequentially 
phosphorylates it and marks it for subsequent ubiquitination and 
proteasomal degradation [146, 147]. Upon Wnt activation however, Dvl 
inhibits the destruction complex causing β-catenin to be 
unphosphorylated enabling its nuclear translocation. FRAT-1 causes 
dissociation of GSK3β from the degradation complex, interfering with 
GSK3β mediated β-catenin phosphorylation, subsequently preventing its 
degradation [148]. At the same time, LRP-5/6 facilitates degradation of 
Axin. The cytoplasmic tail of LRP-5/6 contains residues that become 
phosphorylated upon Wnt ligand binding, effected by GSK3β and CK1 
which in turn creates a binding site for Axin on LRP-5/6 enabling 
recruitment of Axin to the plasma membrane and facilitating its 
degradation [149]. Overall, Wnt activation causes disassembly of the 
destruction complex, thus rescuing β-catenin from degradation [140, 
150].  
Many other co-factors modulate the subcellular location of β-catenin. 
Kramps et al. (2002) identified two segment polarity genes in 
Drosophila – legless (lgs)/homologous to human B-cell CLL/lymphoma-
9 (BCL9) and pygopus (pygo), that were required for nuclear signal 
transduction of Wnt pathway [151] (See Fig 2.2). Their results suggested 
that recruitment of Pygo permitted nuclear β-catenin to activate gene 
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transcription of downstream Wnt target genes [151]. Independently, 
Axin and APC act as nucleo-cytoplasmic shuttles and control subcellular 
localization of β-catenin [152, 153]. Chibby (CBY) inhibits β-catenin-
mediated TCF/LEF transcriptional activation [154]. 14-3-3, which when 
bound to CBY results in its cytoplasmic sequestration, regulates it. 
Moreover, β-catenin, CBY and 14-3-3 form a stable complex that causes 
cytoplasmic partition of β-catenin [155].  
2.1.2 Regulation of transcriptional activation  
When β-catenin is rescued from degradation, it accumulates in the 
cytoplasm and subsequently enters the nucleus where it binds to the 
transcription factors T-cell factor (TCF) and lymphoid enhancer factor 
(LEF) to activate downstream genes [68]. Transcriptional repressors that 
mask the activation site normally block the TCF/LEF. Nuclear β-catenin 
displaces these repressors and other transcriptional co-activators are 
recruited [140]. Transcriptional co-activators include BRM/SWI2-
related gene 1 (BRG-1) which is involved in chromatin remodeling 
[156] and histone acetylase Cyclic adenosine monophosphate (cAMP)-
response element-binding (CREB)-binding protein (CBP)/p300 that 
binds to the β-catenin at its carboxyl domain [157]. In addition, 
BCL9/Legless and Pygopus function to sequester β-catenin in the 
nucleus and modulate its association with TCF [151]. Inhibitor of β-
catenin and TCF (ICAT) inhibits Wnt target gene transcription by 
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preventing the binding of β-catenin with TCF [158] and dissociating the 
β-catenin-LEF-CBP/p300 complex [159]. The TCF function is context 
dependent. TCF complexes with Groucho and acts a Wnt target gene 
repressor when the Wnt signaling is off [159]. However, when the Wnt 
ligand activates Wnt/β-catenin signalling, nuclear β-catenin disrupts the 
Groucho-TCF complex to activate Wnt target gene transcription [159].  
2.1.3 Inhibition of the Wnt/β-catenin signalling pathway  
β-catenin is a powerful nuclear transcription factor that is actively 
degrades in the cytoplasm so that it is prevented from reaching the 
nucleus to transactivate the downstream Wnt target genes [69].  
CK1α and GSK3β operate like a dual-kinase mechanism and 
sequentially phosphorylate β-catenin at its the N-terminal end. Initial 
phosphorylation at Ser45 by CK1α primes β-catenin for subsequent 
phosphorylation at Thr41, Ser37 and Ser33 by GSK3β [147, 160]. β-
catenin phosphorylation at Ser33 and Ser37 generates a docking site for 
the E3-ubiquitin ligase, β-transducin repeat containing protein (β-TrCP). 
This marks β-catenin for subsequent ubiquitination and proteasomal 
degradation [137, 161] (See Fig 2.3). 
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Figure. 2.3 – Wnt ‘off’ state: β-catenin is actively degraded within the 
cytoplasm by in the nucleus or cytoplasm by CK1α and GSK3β in a 
dual-kinase mechanism and mark it for proteasomal degradation in the 
Wnt ‘off’ state. 
 
CK1α and GSK3β also phosphorylate APC and Axin to increase their 
affinity for β-catenin ensuring its phosphorylation and degradation [135, 
147]. Additionally, protein phosphatase-1 (PP1) and protein 
phosphatase-2A (PP2A) are two serine/threonine phosphatases that bind 
with Axin and APC to counteract the actions of CK1α and GSK3β in the 
β-catenin degradation complex. PP1 causes de-phosphorylation of Axin 
and promotes disassembly of the β-catenin degradation complex [162]. 
PP2A on the other hand reduces β-catenin degradation by 
dephosphorylating β-catenin [163].  
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Lee (2003) found intracellular Axin levels to be rate limiting in Wnt 
signalling as there were lower quantities of Axin as compared to the 
quantities of the other members of the degradation complex [164]. Their 
study showed that the half-life of β-catenin halved by increasing the 
concentration of Axin. Such a remarkable effect was not seen in varying 
the amounts of any other component of the degradation complex [164]. 
In the nucleus, the Wnt target genes are maintained in repression by 
TCF/LEF family of proteins [68]. 
2.1.4 Beta-Catenin  
β-catenin is a powerful nuclear transcription factor that is the central 
effector of the canonical Wnt signalling pathway [128]. When the Wnt 
signalling is inactive (absence of Wnt ligand-Fzd interaction), 
cytoplasmic β-catenin is continually degraded by the action of the 
‘degradation complex’ that comprises scaffolding protein Axin, the 
tumor suppressor APC, casein kinase 1α (CK1α), and glycogen synthase 
kinase 3β (GSK3β) [69, 165]. Axin has three separate domains to 
interact respectively with β-catenin, GSK3β and CK1α. In addition, 
Axin interacts with APC through an RGS domain [69].  
Structure of β-catenin 
Beta-catenin, encoded in the humans by the CTNNB1 gene, is a dual 
function protein (781 amino acids) that plays a central role in Wnt 
signalling and cell-to-cell adhesion [128]. It is homologous in 
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Drosophila to the protein armadillo. It also regulates cell adhesion by 
associating with Cadherins and other catenin family of proteins as a part 
of the adherens junction [166]. β-catenin anchors the cadherin complex 
to the actin cytoskeleton by binding to the cytoplasmic domain of E-
cadherin and by forming a complex with α-catenin, [167]. β-catenin is a 
key mediator of Wnt signalling homologous with Armadillo (ARM) of 
Drosophila and β-catenin in Xenopus [168]. 
Different parts of the β-catenin domains play important roles in their 
function (See Fig 2.4). The amino-terminus of β-catenin regulates its 
stability by providing phosphorylation sites for GSK3β and CK1α to act 
on; on the other hand, the carboxyl terminus functions as the 
transcriptional activator domain [68].  
 
Figure 2.4 – Schematic diagram of the structure of β-catenin with its 
various domains and binding partners. 
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A core of 12 ARM repeats is present at the centre of β-catenin, which 
forms a positively charged domain allowing association of multiple β-
catenin binding partners. The N-terminus is vital in determining the fate 
of β-catenin since after phosphorylation by GSK3β and CK1α it gets 
recognized by the β-TrCP ubiquitin ligase which ubiquitinates it and 
destines it for consequent proteasomal degradation [169]. 
β-catenin Phosphorylation 
Under basal conditions phosphorylation status of β-catenin determines 
whether or not it will be degraded by the proteasome. In the Wnt ‘off’ 
state, β-catenin is first phosphorylated by CK1α on the N-terminus at 
Ser45, which primes it and facilitates further phosphorylation of Thr41, 
Ser37 and Ser33 by GSK3β [147, 160] (See Fig 2.5). Phosphorylation at 
Ser37 and Ser33 on β-catenin directs ubiquitination of β-catenin by β-
TrCP causing it to be degraded by the proteasome [161, 165] (See Fig 
2.5). The nuclear import of β-catenin however, requires Rac-JNK-
mediated phosphorylation of β-catenin at Ser191 and Ser605 residues 
[170]. 
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Figure 2.5 – Sequential phosphorylation of β-catenin by CK1α and 
GSK3β 
 
In the Wnt ‘on’ state, phosphorylation at Ser552 promotes nuclear 
accumulation of β-catenin accumulation and increases its transcriptional 
activity [171, 172]. Phosphorylation of β-catenin at Ser552 can be 
facilitated by either Protein Kinase B (Akt) or Protein Kinase A (PKA) 
[173].  
There are two pathways through which β-catenin can be degraded. β-
TrCP and Ebi are two F-box proteins that recognise and bind to the same 
N-terminal domain of β-catenin [174]. Whereas β-TrCP requires prior 
phosphorylation of β-catenin, Ebi is independent of its phosphorylation 
status. Ebi cooperates with Seven in absentia homolog-1 (SIAH-1), 
which itself is induced by TP53 [175, 176]. However, intact APC 
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protein is essential for both pathways [174]. The stabilized cytosolic β-
catenin translocates into the nucleus by a yet not fully understood 
mechanism. Nuclear β-catenin interacts and binds to the TCF/LEF 
family of transcription factors, and activates expression of downstream 
Wnt genes [68].  
2.1.5 Glycogen synthase kinase 3β (GSK3β)  
GSK3β is a serine/threonine kinase that plays a crucial role in the 
stabilization of β-catenin and is a key component of the degradation 
complex. GSK3β phosphorylates β-catenin at Ser33, Ser37 and Thr41 
after a priming phosphorylation at Ser45 by CK1. Phosphorylation at 
Ser33 and Ser37 creates a recognition site for β-TrCP E3-ubiquitin 
ligase that targets β-catenin for proteasomal degradation [160]. It is an 
832 amino acid protein that contains binding sites for β-catenin, Axin 
and Dvl allowing it to form a multi-protein β-catenin degradation 
complex [177-178].  
The stability of GSK3β depends upon its phosphorylation status 
where phosphorylation at Ser9 inactivates it [179]. Phosphorylation at 
Ser9 creates a pseudo-substrate that interferes with its active site thus 
making it incapable to phosphorylate its target proteins, primarily β-
catenin [180]. Numerous other kinases can phosphorylate GSK3β at 
Ser9, and thus regulates its function.  
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Although GSK3β can be phosphorylated at Ser9 by PKA, p90Rsk 
and integrin-linked kinase (ILK) amongst others, the main regulator of 
GSK3β is Akt that inhibits it through the phosphatidylinositide 3-kinase 
(PI3K) pathway [181]. This places GSK3β as a converging point in the 
crosstalk of various signal transduction pathways bringing about 
complex and intricate control of cellular processes. Phosphorylation on 
Ser9 is further enhanced by two further phosphorylation events – 
phosphorylation at Thr43 mediated by extracellular signal regulated 
kinase (ERK); and phosphorylations at Ser389 and Thr390 by p38 
mitogen activated protein kinase (MAPK). Both of these 
phosphorylations further increase Ser9 phosphorylation of GSK3β and 
thus facilitate its inhibition [179].  
Although GSK3β is constitutively active, phosphorylation at Tyr216 
makes it more active by changing the conformation of its active site. If 
there is no phosphorylation at Tyr216, the base of its active site is 
blocked by a side-chain, which diminishes its ability to bind to its 
substrate. The active site is freed up when the Tyr216 residue is 
phosphorylated, allowing easier access by substrates to GSK3β [180, 
182].  
GSK3β is a multifunctional protein and besides β-catenin also 
regulates the intracellular levels of c-myc through its phosphorylation on 
Thr58 that marks it for degradation [180]. Before this can happen, c-myc 
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requires phosphorylation on Ser62 by ERK for its stabilisation. After the 
GSK3β and ERK-mediated phosphorylations, PP2A dephosphorylates at 
Ser62 to allow for subsequent ubiquitination and proteasomal 
degradation [183].  
2.1.6 TCF/LEF Transcription Factors  
The TCF/LEF are a family of nuclear transcription factors that has four 
members: TCF1, TCF3, TCF4, and LEF1 [184]. They are characterised 
by a β-catenin binding domain on the N-terminal and a high mobility 
group DNA binding domain on the C-terminal that associates with the 
nuclear transcription regulating Wnt-responsive elements which in turn 
activates the promoter regions of the target genes such as Cyclin D1 and 
c-myc, thus upregulating their transcription [184-186]. Downstream 
activation of Wnt target genes such as CyclinD1 and c-Myc, may 
regulate many cellular processes including survival, growth, 
proliferation and differentiation. Not surprisingly therefore, 
constitutional activation of Wnt signaling is seen in many different types 
of tumours [69].  
If the β-catenin is not phosphorylated, it escapes ubiquitination by 
β-TrCP and subsequent proteasomal degradation and accumulates in the 
cytoplasm, referred to as stabilization of β-catenin. Stabilized β-catenin 
then translocates into the nucleus and associates with TCF/LEF 
transcription factors [68]. For this interaction to take place, it first has to 
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displace the transcriptional repressors, which mask the β-catenin binding 
site. This process also requires the co-operation of other transcriptional 
co-activators [140].  
The activity of TCF/LEF is modulated by a set of transcriptional 
co-activators (e.g. CBP/p300) and transcriptional repressors (e.g. 
Groucho). After translocating into the nucleus, β-catenin displaces 
transcriptional co-repressor Groucho from the TCF/LEF complex and 
itself binds to the transcriptional activation domain of TCF/LEF [186] 
(Fig 2.2). Transcriptional co-activator CBP/p300 facilitates TCF/LEF-β-
catenin interaction. On the other hand, Nemo-like kinase (NLK)/Nemo 
acts like a Wnt repressor. It phosphorylates TCF/LEF that in turn 
decreases its affinity to form the TCF/LEF-β-catenin complex with DNA 
[128, 140, 187]. Many post-translational modifications are crucial in 
regulating the binding of TCF/LEF transcription factors with their 
transcriptional co-activators or repressors. These include 
phosphorylation, ubiquitination, acetylation and sumoylation [140]. 
Thus, downstream activation of Wnt targets is tightly regulated, given 
their influence on the various growth processes that may promote 
tumour formation if deregulated. 
2.1.7 Wnt Target Genes  
When the Wnt signaling is activated, β-catenin stabilizes in the 
cytoplasm and subsequently translocates to the nucleus, where it 
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engages DNA-bound TCF/LEF transcription factors [188, 189]. The 
TCF/LEF-β-catenin complex then drives the activation of the many 
downstream Wnt target genes that have a wide variety of cellular 
functions [190]. Some of the key target genes are shown in Table 2.1. 
Table 2.1: Wnt target genes, adapted from Nusse’s Wnt Homepage [68] 
 
 
 
 
 
 
 
 
   
Many of the Wnt target genes are specific to a particular tissue or to 
the stage of development; however, Axin2 gene is considered to be a 
general indicator of the Wnt pathway activity [201]. The mechanism of 
the nuclear importation of β-catenin remains unclear, although recently 
it has been suggested that it may be related to microtubules and active 
transport [203]. Interestingly, it has been shown that active Wnt 
signalling may not need an overall demonstrable increase in the level of 
nuclear β-catenin. It has been suggested that fold change rather than 
Gene up/down References 
c-myc up He, 1998 [191] 
Cyclin D up 
Tetsu, 1999 [192];  
Shtutman, 1999 [193] 
 
Tcf-1 up Roose, 1999 [194] 
LEF1 up Hovanes, 2001 [195] Filali, 2002 [196] 
c-jun up Mann, 1999 [197] 
Matrix 
metalloproteinase 
MMP-7 
up Brabletz, 1999 [198] Crawford, 1999 [199] 
Axin-2 
up, feedback 
inhibitor of 
Wnt pathway 
Yan, 2001 [200] 
Lustig, 2002 [201] 
Jho, 2002 [202] 
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absolute levels of nuclear β-catenin may be crucial. This implies that 
nuclear β-catenin even at low levels may be sufficient for transcriptional 
activity without having any constitutionally activating β-catenin 
mutations [204].  
To conclude, Wnt signalling is crucially involved not only in 
development but also in cell fate determination, cell proliferation, 
survival, migration, cell polarity and death; furthermore, dysregulation 
of this pathway may cause cell transformation and tumour formation.  
2.1.8 Role of Wnt signalling pathway in cancer  
Wnt signalling is required for stem cell renewal. Hence, it is not entirely 
unexpected that mutations within the major Wnt proteins like β-catenin, 
APC and Axin frequently lead to cancer, in tissues that require Wnt 
signaling for self-renewal or repair [69]. It is known that deregulation of 
Wnt signalling promotes stromal invasion and metastasis in various 
tumours. This is explained by the fact that the downstream Wnt targets 
regulate a myriad of cellular processes including growth and 
proliferation [69]. In colon carcinomas, APC mutations, a key 
component of the β-catenin degradation complex, results in stabilization 
of β-catenin allowing it to initiate oncogenic transformation [115, 205].  
Anaplastic thyroid cancer shows a high frequency of β-catenin 
mutations with consequent nuclear β-catenin accumulation, which 
supports the role of Wnt activation in its pathogenesis [206]. 
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Additionally, papillary thyroid carcinomas associated with familial 
adenomatous polyposis, a hereditary disorder in which the APC gene is 
mutated, display nuclear β-catenin immunostaining [207]. Previously, 
we have provided evidence for the relevance of the Wnt pathway in the 
regulation of thyrocyte proliferation [208, 209] Inactivation of E-
cadherin appears to be another mechanism by which the 
unphosphorylated cytosolic β-catenin can be stabilized [210].  
Germ line APC gene mutations cause a hereditary cancer syndrome 
known as familiar adenomatous polyposis (FAP) syndrome. FAP 
patients are heterozygous for APC mutations. The loss of the second 
allele in the cells results in colorectal adenomas or polyps, in these 
patients. The adenoma-carcinoma sequence progresses as additional 
mutations accrue in genes like K-ras, p53, and Smad4 [211]. Moreover, 
APC and Axin-2 mutation results in stabilisation of β-catenin and 
resultant constitutively active complexes with Tcf4 [212, 213]. Recently, 
exome sequencing has shown that many of the colorectal cancers 
harbour inactivating APC mutations [69].  
2.1.9 Role of Wnt signalling pathway in normal muscle development  
Embryonic myogenesis is regulated spatio-temporally by a complex 
orchestration of embryonic signalling pathways, which include Wnt 
pathway, Shh pathway and BMP. Wnt signalling is vital during 
development of musculature in the embryo [91]. Wnt pathway controls 
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the expression of certain myogenic regulatory factors (MRFs) like 
MyoD and Myf5, which are essential for myogenic lineage progression 
in the embryonal stage of muscle development [91]. The regulation of 
the myogenic stem cells, also known as the satellite cells, is under the 
influence of canonical Wnt signalling [91]. Many studies using genetic 
knockout models have confirmed the need for several Wnt proteins in 
the normal myogenesis [214, 215]. 
Studies on muscle development on the mice have provided insights 
into the mechanism of muscle development. The mesodermal primary 
germ layer gives rise to the vertebrate skeletal muscle [216]. The 
paraxial mesodermal cells mature to form paired segmental somites 
along the embryonal anterior/posterior axis, which later forms the 
majority of skeletal muscles [217]. The somite gradually patterns into 
the dorsal epithelial dermomyotome and the ventral mesenchymal 
sclerotome. The latter forms cartilages and bones whilst the former gives 
rise to skin and skeletal muscles of the body and extremity [123].  
The expression of Pax3/Pax7 transcription factors direct the 
formation of myogenic precursor cells (MPCs), within the 
dermomyotomes [218]. Myogenic regulatory factors are expressed by 
the delaminating cells of the dermomyotome that repress Pax3/Pax7 and 
promote myotome formation, from which muscles of the limbs develop 
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[219]. During embryonic development, the skeletal muscles of the trunk 
and limb are derived from somites [123, 220-222].  
2.2 Skeletal Muscle Myogenesis 
During embryonal development, the muscle progenitor cells that 
differentiate to form the future skeletal muscles are located in the 
dermomyotomes within the somites [223]. A regulatory network of 
genes including Tbx6, Mesp-b and Ripply1, are involved in the 
determination of dermomyotome and myotome [224]. Skeletal 
myogenesis crucially rests upon the tight regulation of gene sets that 
help the muscle progenitor cells differentiate into myofibres.  
2.2.1 Genetics of muscle development 
Myogenic basic helix-loop-helix (bHLH) transcription factors are a 
group of genes that include Myogenin, MyoD, Myf5 and MRF4. These 
are critical for the formation of skeletal muscle. MyoD and Myf5 are 
initially required for the myogenic progenitors to differentiate into 
myoblasts. Following this, Myogenin helps in the differentiation of the 
myoblast into myotubes [223]. MRF4 is a very important factor that 
ensures the growth and proliferation of myogenic progenitor cells before 
they can differentiate by blocking the transcription of muscle-specific 
promoters [223].  
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The myoblast differentiation occurs in three defined stages. In the 
first stage, the myoblasts exit the cell cycles express regulatory genes 
that drive the second stage differentiation where the myoblasts align 
with each other. In the third stage the myoblasts actually fuse with each 
other to form the myotubes; actin is actively recruited at the plasma 
membrane, which appose closely to form a pore that gradually widens. 
Calcium and certain metalloproteinases are essential for the last stage 
and their regulation may serve as another control of myogenesis. A 
number of genes expressed during myogenesis are being actively 
investigated [223]. 
The genes fall into the following groups: 
1. Myocyte enhancer factor-2 (Mef-2) are transcription factors, which 
promote myogenesis. There are 4 versions of Mef-2 genes in the 
vertebrates; human Mef-2 genes are denoted as MEF2A, MEF2B, 
MEF2C and MEF2D [225].  
2. Serum Response Factor (SRF) induces the expression of striated 
alpha-actin genes [226] through recruitment of androgen receptors [227]. 
Thus, androgens can regulate myogenesis via regulation of the 
expression of striated alpha-actin genes.  
3. Myogenic regulatory factors (MRFs) that include – Myogenin, MyoD 
(Myf3), Myf5 and Myf6, are critical determinants of muscle identity in 
development, growth and regeneration [228]. MyoD has provided a 
 73 
deeper insight into our understanding of the processes of myo-
differentiation [229] when it was shown that transfection of a single 
cDNA could convert fibroblasts into myoblasts [230]. This established 
MyoD as the master regulator of cell fate in myogenesis. Soon the other 
members of the MRFs were identified including Myf5 [231], Myogenin 
[232] and MRF4 [233]. These factors also shared the ability of MyoD to 
convert fibroblasts into myoblasts and activate muscle gene expression. 
Together, these genes are expressed in the myogenic cells during 
embryonic myogenesis [234] albeit at varying stages of myogenesis, 
reflecting subtle differences in the roles during myo-differentiation [235, 
236]. Pestronk described various stages of myogenesis, each of which is 
controlled by a set of defined genes that are critical [237]. The different 
stages with their associated genes are described in Table 2.2. 
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Table 2.2: Genes associated with muscle development [223] 
Stage Associated Genetic Factors 
Delamination PAX3, c-Met 
Migration c-met/HGF, LBX1 
Proliferation 
PAX3, c-Met, Mox2, MSX1, Six1/4, Myf5, 
MyoD 
Determination Myf5 and MyoD 
Differentiation Myogenin, MCF2, Six1/4, MyoD, Myf6 
Specific Muscle Formation Lbx1, Meox2 
Satellite Cells PAX7 
 
2.2.2 Stages of Myogenesis 
2.2.2.1 Delamination 
The main associated genetic factors in this stage are PAX3 and c-Met. 
Pax3 is highly expressed during embryonic stage of development and to 
some extent around the foetal stage. Pax3 is differentially expressed in 
the migrating hypaxial cells and within the cells of dermomyotome, but 
never during facial musculature development [237]. Pax 3 gene is 
needed for the expression of c-Met, which is in turn needed for lateral 
migration. Any mutations in Pax3 may cause aberrant c-Met expression 
resulting in lateral migration defects. PAX3 also mediates MyoD 
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expression, which is one of the master regulators of myoblast cell fate as 
described previously [237].  
2.2.2.2 Migration 
The associated genetic factors in this stage are c-MET and Ladybird 
Homeobox-1 (LBX1). Mutations in c-MET and/or LBX1 can cause 
migration arrest. Since LBX1 is essential for the structural development 
of dorsal forelimb muscles as well as the migration of dorsal muscles 
into the limb [237], any absence of LBX1 results in failure of the limb 
for develop normally. Deletion of LBX1 results in the hind limb muscles 
to be affected severely. As a result, only the flexor compartment muscles 
develop in the forelimb because of the ventral muscle migration [237]. 
c-Met on the other hand, is a receptor tyrosine kinase that is essential for 
the migrating myoblasts to proliferate and survive and requires PAX3 
for its transcription. c-Met deletion curtails secondary myogenesis and 
prevents the formation of muscle in the limbs [237].  
2.2.2.3 Proliferation 
This is an important cell fate of the myoblasts and need the cooperation 
of many genetic factors including Pax3, c-Met, Mox 2, Muscle Segment 
Homolog of Drosophila-1 (MSX1), Six, mesoderm and regional 
specification [237]. Myf5 is required for proper myoblast proliferation 
and is the first myogenic regulator to be expressed. Deletion of Myf-5 
and MyoD results in amyoplasia [237]. 
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2.2.2.4 Determination 
Myf5 and MyoD are myogenic bHLH proteins and their expression is 
tantamount for myogenesis since they make the cell committed to 
muscle development [238]. Co-deletion of Myf5 and MyoD results in 
amyoplasia [239]. Likewise, mutation in either of the two causes cells to 
adopt non-muscular phenotypes [237]. MyoD auto-regulates its own 
gene; the gene product binds to the MyoD gene and induces its own 
production [239]. Myf5 expression is under the control of other 
embryonic developmental pathways such as regulated by Shh, Wnt1 and 
MyoD itself [237].  The correlation of MyoD in the regulation of Myf5 
shows how the two genetic factors are connected [237].  
2.2.2.5 Differentiation 
This is regulated by Myogenin, Mcf2, MyoD, Myf6 and Six. Myogenin 
(Myf4) is required for the fusion of myoblasts. Deletion of Myogenin 
causes a near total loss of expression of differentiated muscle fibers 
severe skeletal muscle hypoplasia in the ventral body wall [237]. Myf-6 
(MRF4) is required for differentiation of myotubes; Myf-6 loss causes 
centronuclear myopathy and Becker muscular dystrophy [237]. 
2.2.2.6 Specific muscle formation 
Mutations in LBX1 and/or Mesenchyme Homeobox 2 (Mox2) may 
affect specific regions of muscular development. Since LBX1 is required 
for the proper formation of the dorsal limb muscles, any disruption of 
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LBX1 gene results in congenital hypoplasia of the musculature of 
extensor compartment of the hind limbs [237]. Mox2 loss on the other 
hand gives rise to abnormal patterning of the limb musculature resulting 
in hypoplasia of the hind limbs and its musculature [237]. 
2.2.2.7 Satellite cells 
Satellite cells are under the regulation of Pax7. Loss of Pax7 function 
would prevent satellite cells formation and consequently cause inhibition 
of postnatal growth of muscle. Satellite cells are hypothesized to be 
quiescent myoblasts that are required for muscle repair but have a very 
limited ability to multiply [237]. Satellite cells can also differentiate into 
metaplastic osseous or adipose tissue [237].  
The muscle differentiation is chiefly under the controls of two 
tightly regulated signal transduction pathways: the PI3K/Akt pathway 
and the Notch/Hes pathway. These signaling pathways cooperate with 
each other to inhibit the MyoD transcription, the master regulator of 
myogenic differentiation [238]. By stabilizing Notch/Hes binding, the O 
subfamily of Forkhead proteins (FOXO) plays a crucial role in 
exercising control over of myogenic differentiation [238]. 
  
 78 
2.3 Does Wnt signalling play a role in RMS? 
β-catenin is a potent nuclear transcription factor that plays a central role 
in the canonical Wnt signalling pathway, which is actively involved in 
muscle development and embryonal somite patterning. Muscle 
development and regulation of its proliferation is precisely controlled. 
Under basal conditions, muscle cells are highly differentiated and rarely 
divide. The mechanisms that regulate this dichotomous fate of muscle 
cell proliferation and differentiation is incompletely understood although 
in recent years new molecular data are emerging which may lead to a 
better understanding of the molecular complexity of this process.  
2.3.1 Wnt genes involved in myogenesis 
Wnt signalling is very important for the embryonic development of limb 
and trunk musculature. Both canonical and non-canonical Wnt signalling 
pathways play essential roles in embryonic myogenesis [222]. 
Myogenesis is influenced by differential Wnt signals expressed 
spatiotemporally within the tissues surrounding the developing muscle. 
Dorsal region of the neural tube expresses Wnt1, Wnt3a and Wnt4 
whereas Wnt4, Wnt6 and Wnt7a are expressed by the dorsal ectoderm 
and Wnt11 within the epaxial dermomyotome [91]. Somitic myogenesis 
is induced by Wnt signals (Wnt1, Wnt3a and Wnt4) that are expressed in 
the dorsal regions of the neural tube in cooperation with Shh signalling 
from the notochord [240]. Brack (2009) demonstrated that for normal 
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myogenesis, a temporal switch is required in myogenic progenitor cells 
from Notch to Wnt signaling [241].  
2.3.2 Muscle specific genes and Wnt pathway 
Crucially, Wnt also regulate the expression of myogenic regulatory 
proteins Pax3/7, MyoD and Myf5, which are essential for myogenesis 
[219, 242, 243]. In mouse model, Wnt1 induces expression of the Myf5 
via the canonical β-catenin pathway [242]. On the other hand, MyoD can 
be also be activated by Wnt7a through a PKC-dependent non-canonical 
pathway under the influence on Pax3 that is β-catenin-independent [244, 
245]. Previously, Borello (1999) demonstrated in a mouse model that 
transplacental delivery of Wnt antagonist Frzb1 inhibits the development 
of skeletal myogenesis [246]. Furthermore, using conditional deletion of 
β-catenin driven by Pax3-Cre/Pax7-Cre, Hutcheson (2009) showed that 
β-catenin is essential for the formation of the myotome [247]. Gros 
(2009) studied chick embryos and found that Wnt11expression in the 
epaxial dermomyotome was required for the development of the 
myotome through the non-canonical PCP pathway. But interestingly, 
Wnt11 expression itself was induced through a β-catenin-dependent 
mechanism involving Wnt1 and Wnt3a from the dorsal neural tube 
[216]. 
 
 
 80 
2.3.3 Rationale for investigating Wnt Pathway in RMS 
There is emerging data that dysregulation of embryonal pathways may 
be central in paediatric tumours. The literature on Wnt pathway in RMS 
is patchy and there is conflicting data as to its therapeutic and prognostic 
significance. However, given the role that Wnt signalling plays in 
embryonal myogenesis and tumourigenesis, this study aims to 
characterise the Wnt pathway in RMS using clinical material and by in-
vitro studies using RMS cell lines in order to improve our understanding 
of the mechanisms underpinning tumourigenesis in RMS. We also 
intend to investigate whether modulation of Wnt pathway could be 
exploited as a viable therapeutic option. 
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CHAPTER 3 – MATERIAL & METHODS  
This collaborative study between groups in Liverpool and Carlo 
Dominici’s group at the University of Rome aims to characterise Wnt/b-
catenin signalling in RMS in order to improve our understanding of the 
mechanisms underpinning tumourigenesis in RMS. The results have 
been published in a journal article in 2013 [248]. 
3.1 Clinical Material 
The sample for the study comprised 54 RMS cases obtained from the 
histopathology archives of Alder Hey Children’s NHS Foundation Trust 
(n=40, 1991–2009) and ‘Policlinico Umberto I’ Hospital, Sapienza 
University, Rome, Italy (n=14; 2005–2009) [248]. Ethical approval was 
obtained from research committees of Alder Hey Children’s NHS 
Foundation Trust and ‘Policlinico Umberto I’ Hospital. Informed 
consent was obtained from all patients or their parents in accordance 
with the guidelines of Children’s Cancer and Leukemia Group (CCLG) 
and United Kingdom Children's Cancer Study Group (UKCCSG). The 
minimum follow-up period of the patients was 5 years. Forty-four cases 
out of 54 had sufficient tissue to be included [248]. Patient data and 
tumour characteristics are presented in Table 4.1. 
RMS was diagnosed in both centres using standard diagnostic 
criteria and was stratified histomorphologically (embryonal, alveolar, 
not otherwise specified); nuclear expression of Myogenin and MyoD1 
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was required for the diagnosis of RMS (Figure 1.1). Pax3/7–FOXO1 
translocation status was assessed using standard FISH analysis, in all 
cases. We used normal skeletal muscle tissue (n=8) obtained at surgery 
for benign conditions from age-matched controls [248]. 
3.2 Cell Culture 
RMS cell lines were used for the in-vitrp studies. We used four RMS 
cells, two from embryonal RMS (RD and RD18) and two from alveolar 
RMS (Rh4 and Rh30). RMS embryonal cell lines were kindly donated 
by Dr P.L. Lollini (from the Department of Experimental Pathology, 
Cancer Research Section, University of Bologna, Italy).  
RD cells are one of the most commonly used cell lines in RMS 
research. RD cell line was established from biopsy material of a 7-year-
old girl with a pelvic RMS that wad previously treated with 
chemo/radiotherapy but was refractory to it [249]. Rh4 (RH41) cell line 
was was established by Dr. Peter Houghton’s laboratory at St. Judes 
Children's Research Hospital (Memphis, Tennesse, USA), from a 7-
year-old girl with alveolar RMS. Rh4 harbors the 
t(2;13)(q35;q14)translocation, representing ARMS [249]. RH30 cell line 
was derived from the culture of bone marrow obtained from a 16-year-
old male with untreated metastatic alveolar RMS. It harbours t(2;13) 
translocation [249]. Details of the RMS cell lines are tabulated in Table 
3.1. 
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Table 3.1: Characteristics of RMS cell lines, their origin and 
karyotype/translocation status [249] 
 
Cell 
Line 
RMS 
subtype 
Origin Karyotype/Gene fusion 
status 
Ploidy and 
doubling time 
Source 
 
RD 
 
ERMS 
 
Derived 
from 
pelvic 
tumour in 
a 7yr old 
girl 
 
 
• MYC (8q24.21) 
amplified and 
overexpressed 
 
• homozygous p53 
mutation 
(R248W) 
 
• heterozygous 
NRAS mutation 
(Q61H) 
 
• p53 OFF, Rb1 
OFF and Ras ON 
sigatures 
 
 
51-
hyperdiploid 
 
#4241949 
 
ATCC  
(cat# CCL-136) 
 
RD18 
 
ERMS 
 
Same 
patient 
above (as 
RD) 
 
 
• Same as above 
 
Same as above 
 
P. Nanni 
(Università di 
Bologna, Italy) 
 
Rh4 
(RH41) 
 
ARMS 
 
Derived 
from 
ARMS in 
a 7yr old 
girl with 
progress-
ive 
disease 
 
 
• Pax3:FOXO1a 
t(2;13) (q35;ql4) 
  
• homozygous p53 
(exon 5-13 bp 
deletion of 
amino acids 150-
154) 
 
Diploid 
 
 
doubling time 
– 60hrs 
 
#6950170 
 
D.N. Shapiro/     
P. Houghton  
(St. Jude); 
www.cogcell.org 
 
Rh30 
 
ARMS 
 
Derived 
from 
untreated 
ARMS in 
a 16 yr 
old boy; 
bone 
marrow 
metastasis 
 
 
• Pax3:FOXO1a 
t(2;13) (q35;q14) 
 
• heterozygous 
p53 (R273C and 
R280S) 
 
• c-MET, GLI, 
CDK4 and 
MDR1 
amplification 
 
 
near triploid 
with 
chromosomes 
between     51-
87 
 
doubling time 
– 35hrs 
 
#3691179 
 
 
P. Houghton/        
T. Look  
(St. Jude); 
www.cogcell.org 
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The cell lines were maintained at 37 °C in 5% CO2 in high 
glucose DMEM medium supplemented with 10% foetal calf serum 
(Sigma, Dorset, UK), 1% L-glutamine, 100 µg/ml streptomycin and 
100 U/ml penicillin. The RMS cells were passaged in T-25 flasks at an 
approximate starting density of 7x105/ml in 3-5mls of DMEM culture 
medium every 3-4 days once they reached a confluence of around 80-
90%. The cell density was counted using a haemocyometer. The cell 
lines were re-suspended in fresh culture 24 hours before the in-vitro 
experiments to ensure optimal exponential growth prior to use [248].  
3.3 Tissue Microarray and Immunohistochemistry 
Tissue microarrays (TMA) using multi-tissue blocks were assembled 
according to tissue array technology developed in the Department of 
Cellular Pathology, Royal Liverpool University Hospital. The TMA 
contained 136 cores from 34 RMS cases. Four cores (1mm deep) were 
selected from the each tumour after reviewing the H&E slides. Sixteen 
cores from eight cases containing normal muscle tissue served as 
controls. Those tumour blocks that were less than 1mm were not 
included for TMA (n=10); instead, full-block sections were used for 
immunohistochemistry [248]. 
Briefly, H&E slides were reviewed for each case and different 
areas of the tumour were marked to account for tumour heterogeneity. 
Corresponding marks were made of the tumour blocks from which the 
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TMA was constructed. Four 1mm cores were punched out from the 
blocks using the TMA punching machine and these cores were 
assembled in a single paraffin block to create a homogenous TMA 
multi-block. The blocks were incubated overnight to set. The blocks 
were then cut on to a microtome to generate 4µm sections after they 
were dewaxed in xylene (10min twice) and rehydrated by graded alcohol 
(20min). Antigen retrieval was done in a microwave oven (20 minutes 
C) in 10mM sodium citrate; pH 6.0). [248] 
Anti-β-catenin primary antibody (1:200, monoclonal mouse anti-
human β-catenin, DAKO, UK) was applied to the sections and 
biotinylated secondary antibodies used for signal amplification 
(Amersham, UK). Endogenous tissue peroxidase activity was blocked 
by incubation with 3% hydrogen peroxide for 8 min. Expressional 
analysis of β-catenin was performed by two independent pathologists 
(blind). [248]. 
The criteria for positivity was defined as at least 10% of the 
tumour cells expressing β-catenin in four representative cores. The 
intensity of β-catenin expression was scored: 0=negative, 1=weak, 
2=moderate, 3=strong [248]. The localisation of β-catenin was defined 
as cytoplasmic/membranous or nuclear. Cases where all four cores were 
not positive for β-catenin expression, only those cases were deemed 
positive for β-catenin where at least three cores showed 2+ expression 
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[248]. The case was considered to be negative if the expression was 
weak (1+). Those cases that were unsuitable for TMA, full-block 
sections (n=10) were examined for β-catenin expression and were only 
regarded as positive if at least 10% cells showed moderate or strong 
expression [248].  
3.4 Protein Extraction  
All RMS cell lines were grown in 100mm culture dishes or T-25 culture 
flasks (Falcon, UK). Once the RMS cells reached 80-90% confluence, 
the growth medium was discarded and cells were washed with sterile 
PBS (8g NaCl, 0.2g of KCl, 1.44g Na2HPO and 0.24g KH2PO4 in 1L 
distilled water, pH 7.4). The RMS cells were detached from the flask by 
incubation with Trypsin (50 µg/ml, Sigma) for 5-10 minutes at 37°C. 
The action of Trypsin was then blocked by adding complete DMEM 
media. Cells were collected by centrifugation at 1000 rpm at 4°C for 5 
minutes. The supernatant was discarded and cell pellets were 
resuspended in one ml PBS, then transferred to 1.5ml eppendorf tubes 
and centrifuged at 3000 RPM at 4°C for 5 minutes.  
Cell scraping (~5 x 106 cells) were obtained from culture flasks 
after trypsinisation and were washed twice with cold PBS. Standard cell 
lysis buffer was used to obtain cellular protein extracts. Cells were lysed 
in 100µl lysis buffer [50mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid/HEPES (pH 7.4), 150mM Sodium 
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Chloride (NaCl), 10% glycerol, 1mM Ethylenediaminetetraacetic acid 
(EDTA), 1% Triton X-100, 1mM Sodium metavanadate (NaVO3), 
100mM Sodium fluoride (NaF), 1mM phenylmethysufonyl fluoride 
(PMSF) and protease inhibitor cocktail (Roche)] [248]. Protease 
inhibitors were added fresh: aprotinin 2µg/ml, leupeptin 2µg/ml and 
2mmol PMSF) at 4°C for 30min. Extracted proteins were stored in lysis 
buffer at -80°C. For in-vitro drug studies, 2 x 106 cells/ml were cultured 
in DMEM supplemented media at 37°C for 24 hours with or without 
200ng/ml of human recombinant Wnt3a or SDF-1 (R&D System). 
3.5 Determination of Protein Concentration 
Protein determination was performed using Bradford colorimetric 
method according to manufacturer’s recommendations (Bio-Rad, Hemel 
Hempstead, Hertfordshire). This method involves the binding of 
Coomassie Brilliant Blue G-250 to amino acids. The binding of the dye 
to proteins causes a shift in the absorption spectrum of the dye from 465 
to 595 nm, and it is the increase in absorption at 595 nm which is 
monitored.  
To determine the unknown quantity of protein in the lysates, a 
standard curve was made from a series of known concentrations of 
Bovine Serum Albumin (BSA) solution (1mg/ml ddH2O) as shown 
below in Table 3.2. The protein sample being tested was made from 5µl 
whole cell protein lysate and 995µl ddH2O. Thereafter, 200µl of the 
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Bradford reagent was added to each of the BSA and the protein samples, 
mixed thoroughly and kept in the dark for 15minutes.  
 
Table 3.2: Concentration of reagents for determine the unknown 
quantity of protein in the lysates 
 
-------------------------------------------------------------------------------- 
Final conc. (µg/ml)    BSA Stock (10µg/ml)     1% Lysis Buffer 
-------------------------------------------------------------------------------- 
0 1000µl ddH20                          - 
0.5 50µl 950µl 
1 100µl 900µl 
1.5 150µl 850µl 
2 200µl 800µl 
2.5 250µl 750µl 
3.0                                  300 µl                            700 µl 
 
To quantify the proteins in the samples 200µl from each of the standard 
and the protein samples were loaded onto a 96-well plate and absorbance 
was read at 595nm in a micro-plate reader using XRead Plus v4.30 
software. Once plotted against the standard curve, results from the 
protein samples represented the amount of total protein present in 5µl of 
the original extracted protein sample.  
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3.6 Western Blot Analysis 
For western blot analysis, proteins (10µg/lane) were resolved in 7.5% 
SDS-PAGE; 10µg proteins in 20µl of radioimmunoprecipitation assay 
(RIPA) lysis buffer (50 mM Tris HCl, (pH 8.0), 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate and 0.1% SDS) were used per lane. Each 
sample was mixed with 5 µl sample buffer (2% SDS, 0.125 M Tris-base 
HCl pH 6.8, 0.001% w/v bromophenol blue, 10% v/v glycerol) and β-
mercaptoethanol (one quarter volume of loading sample buffer), 
vortexed briefly and heated at 100°C for 2 minutes. The samples were 
centrifuged briefly before loading them onto the gel. The denatured 
protein samples were separated by 7.5% Sodium dodecyl sulphate-
Polyacrylamide gel electrophoresis/SDS-PAGE (4.2ml of ddH2O, 3.3 
ml polyacrylamide (30%, Sigma), 2.5ml 1.5M Tris-base HCl pH 8.8, 
100µl of 10% w/v SDS, 50µl of 10% w/v APS (ammonium persulphate) 
and 5µl TEMED (Sigma). TEMED was added just before loading the 
mixture into the gel cassette. The gel was allowed to set for about 45 
minutes. A 4% stacking gel (10ml final volume) was made up of 6.6 ml 
ddH2O, 1.3ml 30% acrylamide (Sigma), 2.5 ml of 0.5M Tris-base HCl 
pH 6.8, 100µl of 10% w/v SDS, 50µl of 10% w/v APS (ammonium 
persulphate) and 10µl TEMED (Sigma). The mixture was poured 
immediately over the resolving gel. A multiwell comb was inserted 
carefully and the gel was allowed to set for 20-30 minutes. The comb 
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was removed and the protein samples were carefully loaded into the 
wells, avoiding any loss or spillage into adjacent lanes. The proteins 
were first allowed to penetrate through the stacking gel by running at a 
low voltage (50 V) for 30 minutes in running buffer (14.4 g glycine 
(Sigma), 3.03 g Tris-base (Sigma) and 10 ml 10% w/v SDS (Sigma) in 
one litre ddH2O). Thereafter, the running voltage was increased to 100-
150V in order to separate the proteins according to their molecular 
weight. The separated proteins were transferred to a polyvinylidene 
fluoride/PVDF membrane (Millipore, Billerica, MA, USA) using 
standard procedures [248]. The protein transfer was done in a transfer 
buffer (14.4 g glycine, Sigma, 3.03 g Tris-base, Sigma and 200 ml 
MeOH in one litre ddH2O) using a 100V current for one hour. After 
blocking with 5% non-fat dry milk in TBS-T buffer (20 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 20-30 minutes with constant 
agitation on a roller, the blots were incubated with the following primary 
antibodies (See Table 3.3 for details of primary antibodies) in the 
blocking solution for either 2 hours at room temperature or overnight at 
4°C with constant agitation. Successful protein transfer was tested by 
soaking the membranes in Ponceau S solution (5% w/v in glacial acetic 
acid, Sigma) for few minutes. The membranes were then washed with 
PBS. As a loading control, membranes were re-probed with 1:1000 
 92 
mouse monoclonal anti-beta-tubulin antibody in the blocking solution 
for one hour at room temperature.  
Table 3.3: Details of the primary antibodies used in western blot 
experiments 
 
Specificity of 
Primary 
Antibody 
Company Catalog 
Number 
Species 
and 
Isotype 
Molecular 
Weight 
(kDa) 
 
Dilution 
Anti-β-catenin 
(L87A12) 
Cell Signalling 
Technology, 
Beverly, USA 
#2698, 
#2698S 
mouse 
monoclonal 
92 1:5000 
Anti-phospho- -
β-catenin 
(Ser552) 
Cell Signalling 
Technology, 
Beverly, USA 
#9566 rabbit 
polyclonal 
92 1:1000 
Anti-phospho- -
β-catenin 
(Ser33/37Thr41) 
Cell Signalling 
Technology, 
Beverly, USA 
#9651 rabbit 
polyclonal 
92 1:1000 
Anti-phospho- -
β-catenin 
(Ser33/37Thr41) 
Cell Signalling 
Technology, 
Beverly, USA 
#9651S rabbit 
polyclonal 
92 1:1000 
Anti-phospho-
Ser9-GSK3β 
Cell Signalling 
Technology, 
Beverly, USA 
#9336 rabbit 
polyclonal 
46 1:1000 
Anti-GSK3β Cell Signalling 
Technology, 
Beverly, USA 
#9315 rabbit 
monoclonal 
46 1:5000 
Anti-phospho-
Akt (Ser473) 
Cell Signalling 
Technology, 
Beverly, USA 
#9271S rabbit 
polyclonal 
60 1:1000 
Anti-Akt Cell Signalling 
Technology, 
Beverly, USA 
#9272 rabbit 
polyclonal 
60 1:1000 
Anti-Slug Cell Signalling 
Technology, 
Beverly, USA 
#9585 rabbit 
monoclonal 
30 1:1000 
Anti-c-jun MBL EP-7186 mouse 
monoclonal 
40 1:1000 
Anti-c-myc MBL M0473 mouse 
monoclonal 
62 1:1000 
Anti-cyclinD1 MBL 553 rabbit 
polyclonal 
36 1:1000 
Anti-Lamin B Abcam, 
Cambridge, 
UK 
ab102036 rabbit 
polyclonal 
71 1:1000 
Anti-Myogenin Merck 
Millipore, 
MAB3876 mouse 
monoclonal 
34 1:1000 
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Germany 
Anti-myoD1 Merck 
Millipore, 
Germany 
MAB3878 mouse 
monoclonal 
45 1:1000 
Anti-myf5 Merck 
Millipore 
Germany 
ABD19 rabbit 
polyclonal 
        29 1:2000 
Anti-desmin Merck 
Millipore 
Germany 
DE-B-5 mouse 
monoclonal 
53 1:2000 
Anti-Axin-1 Cell Signalling 
Technology, 
Beverly, USA 
#2087S rabbit 
monoclonal 
110 1:1000 
Anti-Axin2 Cell Signalling 
Technology, 
Beverly, USA 
#2151S rabbit 
monoclonal 
96 1:1000 
Anti-Naked 1 Cell Signalling 
Technology, 
Beverly, USA 
2201 rabbit 
monoclonal 
59-61 1:2500 
 
Anti-LRP6 
 
Cell Signalling 
Technology, 
Beverly, USA 
 
#3395 
 
mouse 
monoclonal 
 
 
180-210 
 
1:2500 
 
Anti-Dvl-3 
 
Cell Signalling 
Technology, 
Beverly, USA 
 
#3218 
 
rabbit 
monoclonal 
 
 
88-93 
 
1:2000 
 
Anti-β-tubulin      
 
 
Santa Cruz 
Biotechnology, 
Santa Cruz, 
CA, USA 
 
 
Sc-55529 
 
mouse 
monoclonal 
 
51 
 
1:1000 
 
Anti-Pan 
Cadherin 
 
Cell Signalling 
Technology, 
Beverly, USA 
 
#4068 
 
Rabbit 
polyclonal 
 
 
130-150 
 
1:1000 
 
The membranes were then washed three times, for 5 minutes each 
in 0.1% v/v Tween20 in PBS with constant agitation. Then they were 
incubated with the appropriate HRPconjugated secondary antibody 
(Dako) at a dilution of 1:5000 in the blocking solution for one hour at 
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room temperature again with constant agitation. The membranes were 
then washed three times, for 5 minutes each with agitation.  
After incubation with horseradish peroxidase-labeled goat-anti-
rabbit or goat-anti-mouse (1:5000) (GE Healthcare Life Sciences, USA) 
the membranes were developed with enhanced chemiluminescent 
reagent (Pierce Biotechnology, Rockford, USA Amersham, UK). 
Finally, the blots were reprobed using antibodies against -tubulin 
(1:1000); Santa Cruz Biotechnology, Santa Cruz, CA, USA) to ensure 
equal loading and transfer of proteins. All experiments were carried out 
at least three times [248].  
3.7 Dose-response and time-course experiments to see the 
phosphorylation status of β-catenin after human recombinant 
Wnt3a activation:  
Wnt3a is a 44kDa secreted hydrophobic glycoprotein containing a 
conserved pattern of 24 cystience residues [94]. It is a natural agonist of 
the canonical Wnt pathway [134]. It inactivates GSK-3β by disrupting 
the degradation complex allowing free β-catenin to stabilise within the 
cytoplasm and subsequently translocate to the nucleus to activate its 
downstream targets [94, 134]. We prepared a stock solution of human 
recombinant (hr) Wnt3a (R&D Systems, catalog #5036-WN-010) by 
reconstituting 200µg/ml in sterile PBS containing 0.1% BSA. We then 
tried various dilutions of hrWnt3a as recommended by the manufacturer 
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(ED50 <500ng/ml), to activate Wnt signalling in the RMS cells. Western 
blot experiments were designed done to look at the density of β-catenin 
expression ranging from 25-500ng/ml Wnt3a for 24 hrs in RD and Rh30 
cells lines. The lowest concentration giving the maximal response, 
assessed by beta-catenin expression on western blot analysis, was 
200ng/ml and this concentration was then used in all subsequent 
investigations. All experiments were carried out in triplicate. 
 
 
Figure 3.1: RD and Rh30 cells were grown in 6-well culure dishes at 70-80% 
confluence (0.8-1 x 106 cells) and were incubated for 24 hours with increasing doses 
of human recombinant Wnt3a (0, 25, 50, 100, 200 and 500ng/ml) in complete 
DMEM medium supplemented with 10% FCS. After 24hrs the cells were lysed and 
7.5% SDS-PAGE was performed to estimate the total amount of β-catenin using 
mouse monoclonal antibody (1:5000; Cell Signalling). There was a dose-dependent 
increase in β-catenin levels after 50ng/ml in RD cells steadily increasing from 100-
200ng/ml after which is remained relatively constant at higher dosage (500ng/ml). 
Similar effect was seen in Rh30 cells; there was only a mild increase in the amount 
of β-catenin at 500ng/ml as compared to 200ng/ml. The lowest dose showing 
maximal effect in both cell lines by visial inspection was 200ng/ml, hence we used 
this concentration for all further experiments. Beta-tubulin was used as the loading 
control. All experiments were repeated three times. 
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Using a time-course experiment, we assessed the phosphorylation 
status of β-catenin after treatment of the RMS cell lines with human 
recombinant Wnt3a. Rh30 and RD18 cells were stimulated with 
200ng/ml Wnt3a for 0′–10′–30′–60′–180′–300′–12 h–24h after overnight 
serum starvation; untreated Rh30 and RD18 cells served as control. 
Protein extraction and western blotting was performed as described 
above. All experiments were carried out in triplicate [248].  
3.8 Cellular and Nuclear Extracts  
Cellular and nuclear were done as described previously [209]. For 
nuclear and cytoplasmic fractions, three buffers were prepared. Buffer A 
[10mM HEPES pH 7.4, 50mM NaCl, 1mM EDTA, 0.2% Triton X-100, 
500µM Sucrose, 250µM PMSF and protease inhibitor cocktail] was used 
to release nuclei and to recover the supernatant retained as cytoplasmic 
fraction; Buffer B [10mM HEPES pH 7.4, 50mM NaCl, 0.1mM EDTA 
and 25% glycerol] was used to rinse nuclei; and Buffer C [10mM 
HEPES pH 7.4, 350mM NaCl, 0.1mM EDTA, 25% glycerol, 250µM 
PMSF and protease inhibitor cocktail] was used to re-suspend clean 
nuclear pellets [248].  
RMS cells were pre-incubated with or without Wnt3a (200ng/ml) 
in culture flasks. Cell scraping were obtained from T-25 culture flasks 
after trypsinisation and were washed twice with cold PBS. The 
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supernatant was discarded and the cell pellet was collected in a pre-
chilled microcentrifuge tube. The cell pellet was gently resuspend cells 
in 500µl of Buffer A (hypotonic buffer) and was incubated on ice for 15 
minutes. Thereafter, 25 µl detergent (10% NP40) was added and the 
mixture vortexed for 10 seconds. The homogenate was then centrifuged 
for 10 minutes at 3,000 rpm at 4°C. The supernatant constituted the 
cytoplasmic fraction. The pelleted nuclei were rinsed with Buffer B 
three times. They were then resuspended in in 50µl of Buffer C (with 1 
mM PMSF with protease inhibitor cocktail) and incubated in ice for 30 
min. Nuclear extract was collected by centrifugation at 12,000g for 15 
min at 4°C. Protein concentration of the nuclear extract was estimated 
using as described in Section 3.5. The extract was either immediately 
used or stored at -70°C till further use. Aliquots of these samples were 
fractionated by 7.5% SDS-PAGE, electrotransferred to nitrocellulose 
membranes, and analyzed by Western blotting [248].  
3.9 Immunofluorescence  
RD18 and Rh30 RMS cells were seeded and grown to a confluence of 
70–90% on 12-mm glass coverslips placed within 6-well plates. The 
cells were serum-starved overnight and were then treated with 200 ng/ml 
Wnt3a-treated cells (for 6 hrs). Untreated RD18 and Rh30 RMS cells 
served as controls. The cells were then fixed in 4% paraformaldehyde 
for 30 min and permeabilised with 0.1% Triton X-100 in PBS for 5 min 
 98 
at room temperature. The cells were then incubated with: primary rabbit 
polyclonal anti-phospho-S33S37T41-β-catenin antibody (1:1000), 
primary rabbit polyclonal anti-phospho-S552-β-catenin antibody 
(1:1000), primary mouse monoclonal anti-β-catenin antibody (1:1000) 
(Cell Signalling Technology, Beverly, MA, USA); primary mouse 
monoclonal MyHC antibody (Millipore) or TRITC-conjugated 
phalloidin (1:2000) (Sigma-Aldrich), at room temperature for 1 h. After 
washing with PBS, cover slips were incubated with FITC or Texas red-
conjugated goat anti-rabbit secondary antibody (1:2000) (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) for 30 min in the 
dark. After final washing, nuclei were counterstained with Propium 
iodide (PI) or 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). 
The slides were then mounted in Moviol or Vecta Shield and examined 
by immunofluorescence microscopy. All experiments were carried out at 
least three times [248]. 
3.10 Cell Proliferation Assay 
Aliquots of RD18 (4 x103 cells) and Rh30 (3 x 103 cells) RMS cells were 
seeded in triplicate on 96-well plates and incubated with complete 
DMEM medium (with FCS) for 24 h and then starved with serum-free 
medium for 24 h. Quiescent cultures were treated with daily 
supplemented medium with or without 200ng/ml human recombinant 
Wnt3a for 24 and 48 hours. The effect of Wnt3a on cell proliferation 
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was determined by cleavage of tetrazolium salt WST-1 to formazan 
(Roche Applied Science, USA), by reading the absorbance of treated 
and untreated cells at 440 nm. The value for untreated cells was 
considered as 100% cell proliferation. Each point represents a mean 
value and S.D. of three experiments with three replicates [248]. 
3.11 Transfection and Luciferase Reporter Gene Assay 
For the detection of β-catenin-driven Wnt-transcriptional activity, 
Gaussia luciferase assay kit (New England Biosciences, UK) based on 
TOPflash/FOPflash reporter plasmid system was used. Gaussia 
luciferase assay kit (New England Biosciences, UK) based on 
TOPflash/FOPflash reporter plasmid system was used for the detection 
of β-catenin driven Wnt-transcriptional activity [248]. The TOP Flash 
reporter construct contains three optimal copies of TCF/LEF sites 
upstream of a thymidine kinase minimal promoter that, when bound by 
β-catenin induces transcription of luciferase reporter gene. Hence if the 
canonical Wnt signaling is activated, β-catenin will translocate to the 
nucleus to associate with TCF/LEF transcription factors to activate 
transcription of Wnt target genes. Since this is a luciferase plasmid, one 
would see an increase in relative luciferase activity when substrate is 
added. If Wnt signaling is inhibited, one would see loss of luciferase 
expression. The FOPflash is used as a negative control because the TCF 
binding regions upstream of the luciferase gene is mutated so even if β-
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catenin translocates to the nucleus to activate TCF-mediated 
transcription, there will not be any luciferase activity. 
Luciferase reporter gene analysis was performed in control and 
Wnt3a-treated (200ng/ml) RMS cell lines (RD18 and Rh30). A β-
galactosidase vector was co-transfected for standardization. One day 
before transfection, 105 cells/well were seeded per well into 24-well 
plate. After overnight incubation, the cells (90% confluence) were 
transiently co-transfected with 1µg DNA of reporter constructs 
(TOP/FOP Flash) and control plasmid (pCMV-GLuc) using 2µL 
Lipofectamine 2000TM (Invitrogen) in 50µL OptiMEMR I reduced serum 
media, achieving DNA/Lipofectamine 2000TM ratio of 1:2. (Invitrogen). 
Thereafter, the test cells were stimulated with human recombinant 
Wnt3a (200ng/ml) for 48 hours; control cells were untreated. 
Gaussia luciferase has a secretory signal that is secreted into the 
cell medium. Medium from the treated and control cells were collected 
for Gaussia luciferase assay (New England Biosciences, UK) according 
to manufacturer’s instructions. Each assay was performed in triplicate 
and the reporter activity was expressed as mean ± SD [248].  
3.12 Caspase-3/7 Apoptosis Assay 
Apoptosis was measured by Apo-ONE homogeneous caspase-3/7 assay 
according to the manufacturer’s protocol (Promega, UK). Apo-ONE 
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caspase-3/7 reagent was added to serum-starved and Wnt3a-treated 
(200ng/ml) and Rh30 and RD18 cell lines in 96-well plates in a ratio of 
1:1 and incubated for 90 minutes. Appropriate negative controls and 
blank were taken. The fluorescence of each well was measured at an 
excitation wavelength of 485 ± 20nm and an emission wavelength of 
530 ± 25nm. Each assay was performed in triplicate and the reporter 
activity was expressed as mean ± SD [248]. 
3.13 Statistical Analysis 
The experimental results are expressed as mean ± S.D. from at least 
three separate experiments performed in triplicate. Statistical analysis 
was done using Student’s t-test and p-value <0.05 was considered as 
statistically significant [248]. Student’s t-test was done by hand. 
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CHAPTER 4 –  
 
 
RESULTS 
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4.1 Is β-catenin, the central effector of Wnt signalling pathway, 
expressed in the clinical RMS samples? 
In order to characterise Wnt signalling pathway in rhabdomyosarcoma, 
we set out first by investigating if β-catenin, the main effector of Wnt 
signalling pathway, is expressed in the clinical samples (n=44). In order 
to do this, we assembled Tissue microarrays (TMA) containing 136 
samples (four 1mm deep cores per case) from 34 RMS cases from the 
histopathology archives of two major children’s hospital in the UK and 
Italy respectively. Some cases where the thickness was <1mm were not 
included in the TMA; these cases has their full-face sections examined 
(n=10). Positive cases showed at least 10% β-catenin immunopositivity. 
We attempted to separate β-catenin into 3 subcellular 
compartments – membranous, cytoplasmic and nuclear, but the 
distinction between membranous and cytoplasmic compartments was not 
clear in some cases hence for the purpose of for analysis, it was 
considered more pragmatic to group them into one category. The 
membranous/cytoplasmic location represented the inactive form of β-
catenin whereas nuclear β-catenin indicated the active form. Patient 
demographics with details of the tumour subtype, location and the tumour 
genetics is shown in Table 4.1. The sequential steps are shown in Figure 
4.1. Figs 4.2 and 4.3 show TMA assembly and design plan with β-catenin 
score sheet respectively. 
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Table 4.1: Demographic details of the 44 patients on the TMA 
 
 
 
	
 Age Sex Survival DOD/Last 
visit 
Site  Diagnosis Cytogenetics 
1 14y M Dead 08.02.99 Head and neck, Right Zygoma  ERMS  
2 1y 5m M Dead 15.08.98 Perineal  ARMS  Pax 3/7-FKHR positive 
3 6y M Dead 28.04.02 Head and neck, Nose  Botryoid ERMS  
4 12y F Alive 20.01.09 Retroperitoneum, Adrenal region  ERMS  
5 1y 8m M Dead 06.02.00 Pelvic region, near UB  ERMS  
6 18y M Dead 09.04.99 Pelvis/Sarum  ERMS  
7 2y 11m M Alive 27.05.08 Paratesticular  Spindle ERMS  
8 21y M Alive 30.08.05 Paratesticular  ERMS   
9 4y M Alive 18.11.08 Paratesticular  ERMS  
10 3y 1m F Alive 27.02.09 Vagina  ERMS  
11 4y 10m F Alive 16.12.08 Chest wall  ARMS Pax 3/7-FKHR negative 
12 1y 10m M Alive 02.03.09 Parotid  ERMS   
13 13y F Alive 23.10.08 Nose  ERMS   
14 7y M Dead 18.09.08 Nasopharynx  ERMS  
15 2y 10m M Alive 17.02.09 Bladder/Prostate  ERMS  
16 8y F Dead 14.05.05 Infratemporal region  ARMS  Pax 3/7-FKHR positive 
17 7y F Alive 10.02.09 Orbit  ARMS Pax 3/7-FKHR negative 
18 3y 11m F Alive 16.01.09 Zygomatic region  ARMS Ampl of Pax and FKHR, Pax 3/7-FKHR negative 
19 5y 1m F Dead 15.05.08 Ext. ear  ERMS  
20 16y F Dead 12.08.06 Forearm  ARMS Pax3/FKHR positive 
21 8y M Dead 10.08.07 Calf  ARMS Pax7/FKHR positive 
22 7y F Alive 06.01.09 Pelvis/Sarum  ARMS Pax 3/7-FKHR negative 
23 8y M Alive 12.01.09 Maxilla  ERMS  
24 2y 6m M Alive 13.05.08 Mandible  ERMS  
25 10y M Dead 23.01.09 Prostate  ERMS  
26 17y M Dead 15.08.03 Paraspinal mass  ARMS Pax 3/7-FKHR positive 
27 17y M Alive 16.08.05 Nasopharynx  ARMS Pax 3/7-FKHR negative 
28 4y 5m M Alive 02.12.08 Orbit  ERMS  
29 19y F Alive 10.07.06 Pelvis  ERMS  
30 24y M Alive 12.08.03 Paratesticular  ERMS  
31 5y 10m F Dead 13.01.98 Post nasal space  ARMS Pax 3/7-FKHR positive 
32 3y 9m M Dead 03.06.96 Nasal space  ERMS   
33 14y F Alive 10.06.97 Thigh  Anaplastic ERMS  
34 16y M Alive 03.11.08 Paratesticular  Spindle ERMS  
35 4y 11m F Dead 11.11.95 Orbit  ERMS  
36 17y F Alive 04.11.08 Vagina  ERMS  
37 14y F Dead 02.02.95 Foot  ARMS Pax 3/7-FKHR positive 
38 17y M Dead 26.08.96 Neck  ERMS  
39 20y M Alive 27.07.03 Perirectal polyp  ERMS  
40 29y F Alive 28.01.00 Axillary Mass  ARMS Pax 3/7-FKHR negative 
41 17y F Alive 14.04.08 Vagina  Botryoid ERMS  
42 9y M Dead 19.03.03 Palate  ERMS  
43 23y F Alive 28.10.02 Calf  ARMS Pax 3/7-FKHR negative 
44 16y M Dead 28.08.04 Pelvis  Anaplastic ERMS  
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Figure 4.1: Steps in designing of the TMA block cores. 
 
 
Retrieval of histopathology blocks
Marking fresh H&E sections
Designing the TMA
Construction of the TMA
IHC on TMA sections
Scoring and Analysis
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Figure 4.2: Tissue microarray machine (top); paraffin blocks from the RMS cases 
used in the designing of the TMA block cores. 
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Figure 4.3: Design of the TMA block in duplicate (Block 1 above and Block 2 
below) with score sheet for β-catenin expression and its localization within the cell. 
Colour code for pattern of staining: light Green – 1+ staining; green – 2+ staining; 
dark olive green – 3+ staining; yellow – negative; red – no cores. The letters NR, M 
and C indicate β-catenin localisation in nucleus, cell membrane and cytoplasm 
respectively.  
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4.1.1 Immunohistochemical expression of β-catenin in TMA and full-
face sections 
β-catenin expression was evaluated by immunohistochemistry in a total 
of 44 RMS cases; 34 cases were assembled into the TMA multi-block 
and for the remaining 10 cases, full-block sections were assessed. The 
localisation and the intensity of β-catenin expression were recorded 
according to the criteria described in Material and Methods section. In all, 
there were 30 cases of embryonal RMS and 14 cases of alveolar RMS.  
Overall, β-catenin immunostaining was seen in 59% of all RMS 
samples (26/44 cases). When assessed for subtype, however, β-catenin 
expression was higher in alveolar RMS (64%, 9/14 cases) as compared to 
embryonal RMS (56%; 17/30 cases). When assessed for localisation, 18 
out of the 34 RMS samples showed cytosolic/membranous staining for β-
catenin (9 ARMS; 9 ERMS); nuclear localisation was only seen in 2 
cases, both of which were ERMS cases. Of the 10 cases studied using 
full-block sections (all ERMS cases), 6 showed membranous/cytoplasmic 
β-catenin expression; none showed nuclear staining (Figure 2; Table 2).  
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Figure 4.4: IHC scoring for β-catenin expression. Membranous/cytoplasmic and 
nuclear expression patterns and scoring for β-catenin. 
 
PAX–FOXO1 translocation status was known in all ARMS cases 
(n=14) and was carried out by standard FISH analysis as a part of routine 
diagnostic work up of the cases. Half of the alveolar RMS cases (7/14) 
had PAX–FOXO1 translocation (six had Pax3-FOXO1; one had Pax7-
FOXO1). Next, we wanted to see if there was any differential expression 
of β-catenin in the translocation positive and negative ARMS cases. β-
catenin was expressed in five of the seven ARMS cases carrying PAX–
FOXO1 translocations (four in Pax3-FOXO1; one in Pax7-FOXO1) and 
in four of the seven fusion negative-ARMS cases. The results were not 
considered to significant in the small sample studied. 
RMS does not have any activating mutations in Wnt pathway, 
unlike cancers like endometrial carcinoma, colorectal carcinoma, gastric 
carcinoma, anaplastic thyroid carcinoma, Wilms’ tumour or desmoid 
tumours, where there is a dysregulation of Wnt pathway. In these 
tumours, β-catenin is activated constitutively whereby it escapes cytosolic 
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degradation and translocates to the nucleus (showing predominant 
nuclear expression) affecting cellular proliferation and invasion, rather 
than cell differentiation. RMS expectedly does not show nuclear β-
catenin as shown by Bouron-Dal Soglio et al. [250], who found no 
mutations of β-catenin in their RMS cases (n =13). In our study, there 
were only 2 ERMS cases with nuclear β-catenin expression.  
Table 4.2. Immunohistochemical expression of β-catenin in alveolar 
and embryonal RMSs 
 
 
In summary, our results indicate that β-catenin, the key component 
of Wnt signalling pathway, is expressed in around 59% (26/44) of the 44 
cases tested by immunohistochemistry (n=44; 34 TMA cases and 10 full 
face slide sections) (Table 4.2) [248].  
 
 
  
Alveolar RMS 
(n=14) 
Embryonal RMS 
(n=30) 
Total number of RMS cases (n=44) 
 
 TMA cases (n=34) 14 20 
 Non-TMA cases (n=10) 0 10 
    
Membranous/cytoplasmic expression 
 TMA 9 9 
 Full section cases 0 6 
    
Nuclear expression 
 TMA 0 2 
 Full section cases 0 0 
   
Total β-catenin expression (26/44) 9/14 17/30 
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4.2 Are Wnt signalling proteins expressed in the RMS cell lines? 
 
Next, we wanted to see if the major proteins of the non-canonical 
pathway are expressed in RMS cell lines. To this end, we wanted to see if 
the other Wnt proteins besides β-catenin, including the members of the 
degradation complex and Wnt co-receptors, are expressed in the RMS 
cell lines.  
 
4.2.1 Wnt/β-Catenin Signalling proteins are expressed in the RMS 
cell lines 
 The expression of the main components of Wnt/β-catenin pathway was 
tested using immunoblot analysis in four cell lines derived from alveolar 
(Rh4 and Rh30) and embryonal (RD and RD18). Western blot 
experiments demonstrated that β-catenin and its main regulator GSK-3β 
was expressed in all RMS cell lines (Figure 4.5). We further wanted to 
check if cadherin, the main binding partner of β-catenin at the adherens 
junction at the cell membranes, was expressed or not. We also included 
Protein Kinase B/Akt, which itself regulates GSK-3β, in the study to see 
possible interactions with other pathways like IGFR, MAPK and CXCR 
signalling. 
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                   A       B    
 
Figure 4.5: Western blot analysis on the RMS cell lines to demonstrate expression of 
central Wnt regulatory proteins and other Wnt signal-related proteins. Fig 4.5 (A) 
Immunoblot analysis demonstrated the major Wnt signalling proteins, β-catenin and 
its inhibitor GSK3β, in all RMS cell lines. In addition, Akt was expression in all RMS 
cell lines. Cadherin, the main binding partner of β-catenin in the cell membranes, was 
also expression in all RMS cell lines, albeit at a very low signal Rh30 ARMS cell 
line. (B) Further, other Wnt signal-related proteins (Axin1, LRP6, Naked1 and Dvl3) 
could also be demonstrated in all cell lines [B]. Equal amout of protein was loaded in 
all lanes (10µg/lane); β-tubulin served a sthe loading control. The western blot was 
repeated three times. 
 
Cadherin was expressed in all four RMS cell lines, albeit in Rh30 
cell line it was expressed at a lower concentration than the others. But on 
higher exposure, cadherin was detected in Rh30 cells as well (Figure 
4.5a). Other regulatory components of Wnt pathway proteins such as 
Axin-1, Naked-1, LPR6 and Dsh3, were also expressed in all RMS cell 
lines (Figure 4.5b). Thus, the immunoblot analysis confirmed that the 
main Wnt pathway proteins were expressed in human RMS cells.  
Now that we knew that the Wnt proteins were expressed in the 
RMS cell lines, we wanted to investigate further if these constituted a 
functional apparatus for active Wnt signalling to be operative in these cell 
lines. To test this, we used human recombinant Wnt3a, a natural agonist 
of the Wnt pathway, to see if RMS cell Wnt signalling pathway could be 
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activated in-vitro. For all further experiments, we chose Rh30 and RD18 
cell lines representing alveolar and embryonal RMS respectively. 
After standardisation with various dosages ranging from 25-
500ng/ml and timing (0-48 hours), the human recombinant Wnt3a was 
optimised for immunoblot analysis at a dosage of 200ng/ml. We used this 
concentration throughout for the rest of the experiments. The RMS cell 
lines were incubated in serum-starved conditions with 200ng/ml of 
human recombinant Wnt3a to activate Wnt signalling in-vitro.  
4.3 Are Wnt signalling proteins functionally active in the RMS cell 
lines? 
 
To check for Wnt activation first we investigated the phosphorylation 
status of β-catenin and also its localization in ERMS and ARMS. It is 
expected that if Wnt3a activates the signalling, β-catenin should be 
rescued from degradation and the active form of β-catenin should 
translocate to the nucleus. We exploited the use of specific phsopho-β-
catenin antibodies to demonstrate this. 
4.3.1 Phosphorylation Status of β-catenin in response to Wnt3a 
stimulation 
When the Wnt signalling is switched ‘off’, the inactive cytosolic β-
catenin is actively phosphorylated on residues Ser 33, Ser 37 and Thr 41 
by GSK-3β and is targeted for proteasomal degradation [94]. In the 
presence of the Wnt3a ligand, GSK-3β is inactivated that allows 
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unphosphorylated active β-catenin to stabilise and accumulate in the 
cytoplasm. Further, phosphorylation on Ser552 residue, enables β-catenin 
to translocate into nucleus. This is vital for it to bind to TCF/LEF and 
transactivate its downstream targets [172].  
By designing time-course immunoblot analyses, we checked the 
phosphorylation status of the β-catenin after Wnt3a activation to test the 
activation status of Wnt pathway. We found that in the control Rh30 cells 
(0′) there was a pronounced expression of phospho-S33-S37-T41-β-
catenin that gradually decreased between 10′ and 180′. The level was 
very faint at 60′ (Figure 4.6). The values gradually increased between 
180’ and 24hrs. The phospho-S552-β-catenin showed a minimal increase 
in the Rh30 cells between 180’-300’. The total β-catenin remained 
relatively constant. It was expected that in response to Wnt3a, the 
inactive phosphorylated Ser9-GSK-3β levels would increase, however, its 
level decreased. Total GSK-3β levels remained relatively constant 
(Figures 4.6). There was steady reduction in the levels of Akt and 
phospho-Akt up to 60′, after which the levels fluctuated over the 24hrs. 
Comparable changes were seen in the phosphorylated forms of β-catenin, 
GSK-3β and Akt in RD18 cells, albeit with slightly different kinetics 
(Figure 4.6). Phospho-S33S37T41-β-catenin reduced significantly at 30’ 
and gradually returned back over 24hr period. The phospho-S552-β-
catenin showed a very faint increase in the RD18 cells over 24hrs 
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Figure 4.6: Western blot analysis on the RMS cell lines (RD18 and Rh30) to show 
time-course fluctuations in the levels of total β-catenin, phospho-β-catenin-
S33S37T41 (inactive form), phospho-β-cateninS552 (active form); GSK3β; phospho-
GSK3β (inactive form); Protein kinase B/Akt and its phosphorylated form (active), in 
response to Wnt3a (200ng/ml) at different time periods over 24 hours. After treatment 
with Wnt3a, there was a decrease in the level of phospho-β-catenin-S33S37T41 in 
Rh30 and RD18 cell lines. On the other hand, phospho-β-catenin-S552 showed a faint 
increase in Rh18 and RD18 cells. The level of total β-catenin remained relatively 
constant throughout. Equal amount of protein was loaded in all lanes (10µg/lane). The 
experiment was repeated three times. 
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Taken together, the results indicate that is appreciable change in 
the phosphorylation status of β-catenin indicating in response to human 
recombinant Wnt3a in both RMS cell lines. 
4.3.2 Effect of Wnt-3a on the subcellular localisation of β-Catenin 
The sub-cellular localisation of β-catenin reflects its activity within the 
cells (Klaus, 2008; Lu, 2011). We performed immunofluorescence 
experiments to assess the sub-cellular location of β-catenin after 
activation of Wnt signalling through Wnt-3a treatment. There was a 
convincing redistribution of β-catenin within cells upon Wnt3a 
stimulation. β-catenin translocated from the membranous/cytolsolic to 
perinuclear/nuclear location in Rh30 cells (Figure 4.7). This shift in the 
localisation of β-catenin was supported by immunoblot analysis using 
nuclear and cytosolic extracts. (Figure 4.8) This proved that not only is 
there a change in the phosphorylation state of β-catenin, there also is a 
change in its intracellular localisation. 
 117 
 
 
Figure 4.7: Immunofluorescence experiment to demonstrate changes in the sub-
cellular localisation of β-catenin in Rh30 cells in response to Wnt3a. The image on 
top (Rh30 control; without Wnt3a) shows a predominantly membranous expression 
for β-catenin. The image in the bottom shows Rh30 treated with Wnt3a (200 ng/ml 
for 6hrs) show nuclear localisation of β-catenin, indicating active tranlocation of β-
catenin in response to Wnt3a. Mouse monoclonal primary anti-β-catenin antibody 
(1:1000) and FITC-conjugated goat anti-mouse secondary antibody (1:2000) was used 
for localisation of β-catenin. Propium iodide was used for nuclear counterstaining. 
The experiment was repeated three times. 
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Figure 4.8: Immunoblot analysis of total and phosphorylated forms of β-catenin 
protein in the cytoplasmic (C) and nuclear (N) fractions of RD18 and Rh30 cells in 
response to Wnt3a. Total β-catenin and phospho-β-catenin proteins (S552 and 
S33S37T41) were investigated in response to Wnt3a (200ng/ml) in RD18 (top; 0-180 
mins) and Rh30 (bottom; 0-300 mins) by immunoblotting. There were appreciable 
changes in the sub-cellular localisation of β-catenin in both cell lines. There was a 
predominantly membranous expression for β-catenin in untreated control cells. After 
treatment with Wnt3a, the cells showed nuclear localisation of β-catenin, in a time-
dependent manner. There were demonstrable changes in β-catenin 
phosphorylation/de-phosphorylation status in response to Wnt3a, albeit at different 
times in both cell lines. Equal amout of protein was loaded in all lanes (10µg/lane); β-
tubulin and Lamin B served as the loading controls for the cytoplasmic and nuclear 
fractions respectively. The experiment was repeated three times. 
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Figure 4.9: Expressional analysis of phospho-β-catenin-Ser33Ser37Thr41 (inactive 
form of β-catenin) in Rh30 cells in response to Wnt3a by immunofluorescence. There 
was a reduction in the amount of cytosolic S33S37T41-phospho-β-catenin in response 
to Wnt3a. The image on left (Rh30 control; without Wnt3a) showed a higher 
cytosolic expression of phospho-β-catenin-Ser33Ser37Thr41 as compared to Rh30 
cells treated with Wnt3a (200ng/ml for 60 mins; image on the right). Changes in the 
phosphorylation status of β-catenin suggest an active Wnt signalling in Rh30 cell line.  
Rabbit polyclonal primary anti-phospho-β-catenin-Ser33Ser37Thr41 antibody 
(1:1000) and FITC-conjugated goat anti-rabbit secondary antibody (1:2000) was used 
for localisation of phospho-β-catenin-Ser33Ser37Thr41. DAPI was used for nuclear 
counterstaining. The experiment was repeated three times. 
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Figure 4.10: Expressional analysis of phospho-β-catenin-Ser552 (active form of β-
catenin) in Rh30 cells in response to Wnt3a by immunofluorescence. There was an 
increased in the amount of nuclear phospho-β-catenin-Ser552 in response to Wnt3a. 
The image on left (Rh30 control; without Wnt3a) showed a lower nucler expression 
of phospho-β-catenin-Ser552 as compared to Rh30 cells treated with Wnt3a 
(200ng/ml for 120 mins; image on the right). Changes in the phosphorylation status of 
β-catenin suggest an active Wnt signalling in Rh30 cell line. Rabbit polyclonal 
primary anti- phospho-β-catenin-Ser552 antibody (1:1000) and TRITC-conjugated 
goat anti-rabbit secondary antibody (1:2000) was used for localisation of phospho- 
phospho-β-catenin-Ser552. DAPI was used for nuclear counterstaining. The 
experiment was repeated three times. 
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Figure 4.11: Expressional analysis of phospho-β-catenin-Ser33Ser37Thr41 (inactive 
form of β-catenin) in RD18 cells in response to Wnt3a by immunofluorescence. There 
was a reduction in the amount of cytosolic S33S37T41-phospho-β-catenin in response 
to Wnt3a. The image on left (RD18 control; without Wnt3a) showed a higher 
cytosolic expression of phospho-β-catenin-Ser33Ser37Thr41 as compared to RD18 
cells treated with Wnt3a (200ng/ml for 30 mins; image on the right). Changes in the 
phosphorylation status of β-catenin suggest an active Wnt signalling in RD18 cell 
line. Rabbit polyclonal primary anti-phospho-β-catenin-Ser33Ser37Thr41 antibody 
(1:1000) and FITC-conjugated goat anti-rabbit secondary antibody (1:2000) was used 
for localisation of phospho-β-catenin-Ser33Ser37Thr41. DAPI was used for nuclear 
counterstaining. The experiment was repeated three times. 
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Figure 4.12: Expressional analysis of phospho-β-catenin-Ser552 (active form of β-
catenin) in RD18 cells in response to Wnt3a by immunofluorescence. There was an 
increased in the amount of nuclear phospho-β-catenin-Ser552 in response to Wnt3a. 
The image on left (Rh30 control; without Wnt3a) showed a lower nucler expression 
of phospho-β-catenin-Ser552 as compared to Rh30 cells treated with Wnt3a 
(200ng/ml for 30 mins; image on the right). Changes in the phosphorylation status of 
β-catenin suggest an active Wnt signalling in RD18 cell line. Rabbit polyclonal 
primary anti-phospho-β-catenin-Ser552 antibody (1:1000) and TRITC-conjugated 
goat anti-rabbit secondary antibody (1:2000) was used for localisation of phospho- 
phospho-β-catenin-Ser552. DAPI was used for nuclear counterstaining. The 
experiment was repeated three times. 
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We also looked at the localisation of the phosphorylated forms of 
β-catenin using immunofluorescence experiments. Wnt3a stimulation 
increased perinuclear localisation of phospho-S552-β-catenin; at the same 
time, it decreased the level of cytosolic phospho-S33S37T41-β-catenin in 
both alveolar and embryonal cell lines, whereas the amount of control 
nuclear protein Lamin B remained unchanged (Figure 4.9-4.12). Wnt3a 
was added to the cell medium of the RMS cells for 60’, as this was the 
most responsive time period as inferred from the previous time course 
experiments. 
The results from the immunoblot analysis indicate that not only are 
the Wnt proteins expressed in the RMS cells lines, they also show change 
in functional phosphorylation status in response to the natural Wnt 
agonist Wnt3a at a concentration of 200ng/ml. Whilst there was an 
increase in the inactive phospho-S33S37T41-β-catenin in the control 
(Wnt off) state, in the activated state (Wnt on) there was an appreciable 
decrease in the cytosolic levels. Further, there was a physical change in 
the intracellular location of β-catenin in response to Wnt3a as confirmed 
by the cell fractionation analysis and confocal analysis. 
After establishing that the central Wnt proteins are expressed in 
RMS cell lines; that they show change in their phosphorylation status and 
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that there is a shift in their subcellular locations upon Wnt3a activation, 
we wanted to see next if β-catenin was functionally active in the nucleus. 
4.4 Does β-catenin bind to the TCF/LEF in the nucleus and activate 
downstream Wnt targets in the RMS cell lines? 
To evaluate the functional significance of nuclear β-catenin in RMS cell 
lines after Wnt3a-mediated activation, we employed luciferase-based 
TOP/FOP Flash reporter gene assay. Gaussia Luciferase (GLuc) is a 
naturally secreted protein produced by Gaussia princeps. The assay 
principally employs two reporter plasmids – the TOPflash (which 
contains two sets of 3 copies of the wild-type TCF binding regions; acts 
as the positive control) and the FOPflash (that contains truncated TCF 
incapable of binding to the transactivation domain of β-catenin; acts as 
the negative control). If the canonical Wnt signaling is activated, β-
catenin would translocate to the nucleus to associate with TCF/LEF 
transcription factors and would activate downstream Wnt target genes, 
resulting in an increased luciferase activity when the substrate is added. 
On the other hand, there would be a loss of luciferase expression, if Wnt 
signaling is inhibited. Increased FOP flash activity indicates non-specific 
activation of the TCF/LEF under experimental conditions. 
4.4.1 Regulation of TCF/LEF Transcriptional Activation 
Luciferase reporter gene analysis was performed in control and Wnt3a-
treated-RMS cell lines (RD18 and Rh30); β-galactosidase vector was co-
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transfected for standardisation. Rh30 and RD18 cells were stimulated by 
Wnt3a (200ng/ml for 48 hours) after TOP flash-transfection to see if 
there was any change in the reporter gene activity. The control RMS cells 
were untreated. Gaussia luciferase has a secretory signal that is secreted 
into the cell medium. Medium from the treated and control cells were 
collected for Gaussia luciferase assay (New England Biosciences, UK) 
according to manufacturer’s instructions. Each assay was performed in 
triplicate and the reporter activity was expressed as mean ± SD [248].  
We found a 7-fold increase in the reported gene activity in test cells as 
compared to the untreated control cells in both cell lines. On the other 
hand, there was no significant difference in the reported gene activity 
after the transfection of FOP flash control vector. This shows the 
specificity of β-catenin-driven nuclear transcription (Figure 4.13a) [248].  
Immunoblot analysis for Wnt targets showed minor transient 
changes in the levels of c-Jun, cyclin D1, slug and c-myc expression over 
the first 30 minutes (Figure 4.13b). However, the expression of Axin-2 
(Wnt inhibitor) was remarkably increased in Rh30 and RD18 cell lines 
following Wnt3a stimulation on immunoblot analysis, indicating a 
specific downstream effect (Figure 4.13c) [248].  
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Fig 4.13 (a) Functional activation of Wnt signaling in control (untreated) and treated 
(Wnt3a 200 ng/ml for 48hrs) Rh30 (dark grey) and RD18 (light grey) cell lines. Rh30 
and RD18 cells were transfected with TOPflash (positive control) and FOPflash 
reporter (negative control) plasmids (n=3), according to the manufactuer’s 
instructions, and were grown for 48hrs without or with Wnt3a. After Wnt3a 
stimulation, TOP flash-transfected Rh30 and RD18 cells, showed approximately 
seven-fold significant induction of β-catenin-driven TCF/LEF luciferase activity 
compared with untreated control cells; this effect appears to be specific because 
Wnt3a treatment did not affect luciferase activity of FOPflash control vector in both 
cell lines. Data shown are mean ± SD of 3 independent experiments. (b) Immunoblot 
analyses of Wnt target proteins (c-jun, c-myc, cyclinD1 and slug) in Rh30 and RD18 
cell lines, in response to Wnt3a stimulation over time (0-24 hrs). There were minor 
transient fluctuations over 30 mins but there was no sustained effect. Equal amount of 
protein was loaded in all lanes (10µg/lane). β-tubulin served as the loading control. 
The experiment was repeated three times. 
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Fig.14.3 c: Expression of Wnt-feedback inhibitor Axin-2 in Wnt3a stimulated Rh30 
and RD18 cells as compared to untreated controls. Increased expression of Wnt-
feedback inhibitor Axin-2 in Rh30 and RD18 cells treated with Wnt3a (200 ng/ml for 
24 hrs) indicate functional activation of downstream Wnt target genes. Equal amount 
of protein was loaded in all lanes (10µg/lane). β-tubulin served as the loading control. 
The experiment was repeated three times. 
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4.5 What effect does activation of Wnt signalling pathway have on 
the proliferation of RMS cell lines? 
 
Wnt signalling is an important cell fate determinant. Since Wnt pathway 
drives many tumours, next we set out to see what impact it has on the 
proliferation rate of RMS cell lines. It was expected that Wnt3a treated 
RMS cells may activate proliferation as compared to the control cells and 
may shed important insights into the pathogenesis of RMS. 
4.5.1 Effect of Recombinant Wnt-3a on Proliferation and Apoptosis 
in RMS Cell Lines 
We checked for proliferation rate in RMS cell lines after treating them 
treated with Wnt3a over a period of 24-72hrs. Since the reported gene 
mediated nuclear transactivation was maximum after 48hrs, we expected 
to see the maximum change in proliferation rate during this period. 
However, there was approximately 20% decrease in proliferation rates of 
both alveolar RMS cell lines, (Rh4 cells P<0.02 and Rh30 P<0.05; Figure 
4.14). There was no significant decrease in proliferation after Wnt3a 
treatment in the embryonal RMS cell lines (RD18 and RD; Figure 4.14).  
Since the results were unexpected, the experiment was repeated 
thrice at both University of Liverpool and at La Sapienza University 
Rome, given the implications of such a finding. To ensure that the 
decrease in proliferation was not due to cell toxicity or due to increased 
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apoptosis, we did morphological analysis by phase contrast microscopy 
and the Caspase 3/7 assay to address these issues.  
To further characterise the mechanism(s) by which Wnt activation 
may have brought about a decrease in the proliferation rate in the alveolar 
RMS cell lines, we performed apoptosis assay to exclude any toxic or 
cytostatic effects on the cells. There was no significant difference in the 
Caspase3/7 activity after Wnt3a stimulation in any of the RMS cell lines 
suggesting that Wnt3a could have had an effect on the cell differentiation. 
To prove this, we looked at the myogenic differentiation markers in the 
RMS cell lines before and after Wnt3a treatment. To our surprise, we 
found that, after Wnt3a treatment over a period of 24-48 hours, there is a 
definite increase in the expression of early myogenic differentiation 
markers (MyoD1, myf5 and Myogenin), where a late differentiation 
marker desmin showed variable results in both cell lines (Figure 4.15).  
Next, we looked at the myosin and actin arrangement using  
immunofluoresence experiments using MyHC antibody and phalloidin 
TRITC-conjugated after 96 h Wnt3a treatment. Treated cells were MyHC 
positive compared with untreated cells (data not shown) and, after 
phalloidin staining, areas characterised by a more concentrated assembly 
of actin bundles appeared (Figure 4.16a). Cells treated with Wnt3a 
revealed morphological features typical of differentiating muscle cells, 
progressively changing from fusiform or star shaped into elongated 
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confluent cells as shown by confocal microscopy (Figure 4.16b). 
Therefore, increased differentiation appears to be the most plausible 
explanation for the decline in proliferation in alveolar RMS cell lines.  
Overall, We found a 20% decrease in the proliferation rate in the ARMS 
cells treated with Wnt3a (200ng/ml) for 48-72 hours as compared to the 
untreated control ARMS cells. There was an increase in the muscle 
differentiation markers during this period; there was no significant 
increase in the rate of apoptosis in test or control cells (Fig 4.17).  
 
 
     
Figure 4.14: Effect of Wnt3a (200 ng/ml) on the proliferation of alveolar (Rh4 and 
Rh30) and embryonal (RD and RD18) RMS cell lines expressed as % inhibition. 
There was 15–20% decrease in proliferation rate of alveolar RMS cells (Rh4 P<0.02 
and Rh30 P<0.05) and no significant change in embryonal RMS cells (RD P>0.05 
and RD18 P>0.05; n=3). Data shown are mean ± SEM of 3 independent experiments.  
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4.5.2 Expression of muscles-specific markers in response to Wnt 
activation 
We also performed IF experiments using MyHC antibody and phalloidin-
conjugated to show actin and myosin arrangement. 96h Wnt3a treated 
cells showed induction of MyHC protein and reorganization of actin 
fibers typical of myo-differentiation (Figure 4.15). Based on these data, 
the decrease in proliferation rate appears to be related in ARMS to an 
increase in cell differentiation rather than toxic cell death or apoptosis. 
Thus, it appears possible that Wnt pathway expression in RMS may be in 
a functionally repressed state (possibly from antagonistic activity of other 
pathways active in RMS like MAPKinase/Ras pathway or CXCR 
pathways etc.)  
Our results in RMS cell lines indicated that activation of Wnt 
pathway (by Wnt agonist Wnt3a) can increase muscle differentiation in 
vitro and can decrease the cell proliferation; there was no increase in the 
rate of apoptosis between control and test cells after 200ng/ml of Wnt3a 
for 48 hours.  
Thus, functional activation of Wnt pathway by the Wnt agonists 
(like LiCl, BIOS, Sodium Valproate etc.), may have a therapeutic role in 
RMS in the future.  
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Figure 4.15: Increased expression of myogenic markers (Myogenin, Myf-5 and 
MyoD1 and desmin) after Wnt3a (200 ng/ml for 24 and 48hrs) stimulation in 
rhabdomyosarcoma (RMS) cells as compared to the untreated control cells (at 0 hrs). 
Equal amount of protein was loaded in all lanes (10µg/lane). β-tubulin served as the 
loading control. The experiment was repeated three times. 
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Figure 4.16a: The effect of Wnt3a stimulation (200ng/ml for 96hrs) on Rh30 cells. 
Actin rearrangement to form condensed filamentous bundles (arrows) is shown by 
immunofluorescence with TRITC-conjugated phalloidin. The experiment was 
repeated three times. 
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Figure 4.16b: The effect of Wnt3a stimulation (200ng/ml for 96hrs) on Rh30 cells. 
Phase contrast microscopy shows a change in morphology from stellate to elongated 
cells. Representative images for each treatment group are shown with the areas in the 
upper panels enlarged in the lower bottom panels. Scale bars 20µm. The experiment 
was repeated three times. 
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Figure 4.17: The effect of Wnt3a stimulation (200ng/ml for 48 hrs) on Rh30 and 
RD18 cells. Caspase3/7 assay does not show any significant increase in the apoptosis 
to account for the decrease in the proliferation rate seen in the both RMS cell lines. 
Data shown are mean ± SEM of 3 independent experiments.  
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4.6 Does Wnt signalling pathway cross-react with CXCR pathway in 
RMS cell lines? 
Chemokines are small pro-inflammatory cytokines that regulate cell 
trafficking and adhesion by binding to specific G-protein coupled 
transmembrane receptors [251]. The chemokine CXCL12 or SDF-1 
(stromal-derived factor-1) is an important α-chemokine that is secreted by 
bone marrow stromal cells [252]. It binds to its receptor CXCR4 and is 
believed to play an important role in bone marrow metastasis [253, 254]. 
By induction of VLA-4 and LFA-1 integrins on the surface of CD34 
cells, SDF-1 promotes these cells to migrate and home in to the bone 
marrow endothelium [255].  
It has been proposed that SDF-1/CXCR4 axis may facilitate 
multiple stages of metastasis, including adherence to endothelium, blood 
vessel extravasation, angiogenesis, proliferation and evasion of host 
defence mechanism [251, 256]. CXCR4–SDF-1 axis has been implicated 
in the metastasis of breast cancer and RMS to bone marrow and lymph 
nodes that naturally express high levels of SDF-1 [257-259]. 
Interestingly, there are some studies in the literature that link SDF-
1/CXCR4 axis with Wnt/b-catenin signalling. SDF-1/CXCR4 signalling 
has been shown to stimulate the activity of b-catenin in the neural 
progenitor cells of rat [260]. Wang (2007) showed the relevance of SDF-
1/CXCR4 signalling in metastasis of pancreatic cancer [261, 262]. 
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The downstream effectors of CXCR4 in RMS have not been 
clarified completely and have mainly been linked to the stimulation of 
survival pathways such as ERK/MAPK, PI-3K/Akt/mTOR, and/or 
Jak/STAT with activation of downstream genes like c-Myc and cyclin D1 
[251, 263, 264]. Many of these pathways cross talk with Wnt/b-catenin 
signalling. One would expect that if the PI3K/Akt pathway is activated, it 
would inhibit GSK3b (a protein which promotes cytosolic b-catenin 
degradation) and would allow nuclear translocation of b-catenin that 
stimulates downstream genes such as c-Myc and cyclin D1.  
Miekus (2013) demonstrated induction of myodifferentiation with 
reduced MyoD expression upon down regulation of the c-MET receptor 
[59]. He also showed reduced metastatic potential of ARMS cells to the 
bone marrow with down regulation of CXCR4 receptor expression [59]. 
He proposed the clinical utility of c-MET receptor inhibition and 
activators of myodifferentiation in RMS. Since β-Catenin is known to 
regulate MyoD transcription, and since CXCR4 expression in ARMS is 
related to bone metastasis, we wished to exclude any potential cross talk 
between the Wnt and SDF-1/CXCR4 pathways. 
It is expected that if a cross talk exists between Wnt/b-catenin and 
SDF-1/CXCR4 axis and that if the SDF-1 mediates its effects in RMS via 
the PI3K/Akt pathway, there should be appropriate changes in the 
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phosphorylation status of β-catenin, GSK3β, Akt and Erk. Also there 
should be increased expression of the downstream Wnt targets, c-Myc 
and Cyclin D1. 
4.6.1 Time-dependent expression of SDF-1 in RMS cell lines after 24 
hours of Wnt3a stimulation in vitro. 
Since Wnt pathway is associated with myogenesis and also with 
increased myogenic differentiation we wished to investigate if CXCR4–
SDF-1 axis cross talks with Wnt signalling in RMS. To this end, ARMS 
cell line RH30 and ERMS cell line RD18 were treated with human 
recombinant SDF-1 (200ng/ml) for 24 hours and cell lysates were 
prepared at 0’, 10’, 30’, 60’, 180’, 300’, 12hrs and 24hrs to see time 
dependent changes in the various Wnt proteins by western blotting (beta-
catenin, pS33S37T41phospho-beta-catenin, pS552phospho-beta-catenin, 
GSK3beta, S9phospho-GSK3beta, CyclinD1 and c-Myc), Protein Kinase 
B/Akt, phospho-Akt, ERK1/2 and phospho-ERK1/2.Beta-tubulin served 
as the loading control.  
Results did not indicate any significant change in any of the Wnt 
proteins or their phosphorylated forms in response to SDF-1 in-vitro in 
ARMS cell line RH30. Total β-catenin and its phosphorylated forms, 
pS33S37T41phospho-β-catenin and pS552phospho-β-catenin did not 
show any appreciable change over time with SDF-1 treatment. Similarly, 
 139 
protein levels of total GSK3β and its phosphorylated form S9phospho-
GSK3β remained constant. Total ERK and phopsho-ERK1/2 however, 
increased strongly at 10’ until 30’. Whereas phospho-ERK reduced 
sharply after an hour and disappeared over 24 hours, total Erk reduced 
gradually returned to basal level over 24 hours. Downstream Wnt target 
Cyclin D1 expressed sharply around 180’, peaked at 300’ and then started 
falling after 12 hours to disappear by 24 hours of SDF-1 treatment. C-
Myc levels were difficult to assess; the expression dropped between 60’ 
and 300’ and returned to basal levels by 24 hours. β-tubulin served as 
loading control. 
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Figure 4.18: Western blot analysis on the RMS cell lines. Levels of β-catenin, 
phospho-β-cateninS33S37T41 (inactive form), phospho-β-cateninS552 (active form); 
GSK3β; phospho-GSK3β (inactive form); Protein kinase B/Akt and its 
phosphorylated form (active); Erk and its phosphor form and downstream Wnt targets 
(cyclin D1 and c-myc) are seen in response to Wnt3a (200ng/ml for 24hrs) in Rh30 
cell line. Equal amount of protein was loaded in all lanes (10µg/lane). β-tubulin 
served as the loading control. The experiment was repeated three times. 
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Figure 4.19: Western blot analysis on the RMS cell lines. Levels of β-catenin, 
phospho-β-cateninS33S37T41 (inactive form), phospho-β-cateninS552 (active form); 
GSK3β; phospho-GSK3β (inactive form); Protein kinase B/Akt and its 
phosphorylated form (active); Erk and its phosphor form and downstream Wnt targets 
(cyclin D1 and c-myc) are seen in response to Wnt3a (200ng/ml for 24hrs) in RD18 
cell line. Equal amount of protein was loaded in all lanes (10µg/lane). β-tubulin 
served as the loading control. The experiment was repeated three times. 
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In the RD18 cell line, apart from Ser9-phospho-GSK3β, which 
showed time dependent decrease over 24 hours, there were no significant 
changes in any of the Wnt proteins or their phosphorylated forms. 
Phospho-Akt and phopsho-ERK1/2 levels remained unchanged.  
Hence, we did not find any evidence of cross talk between CXCR4 
and Wnt signalling pathway. 
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CHAPTER 5 – DISCUSSION 
β-catenin is a potent nuclear transcription factor that mediates the 
canonical Wnt signalling pathway, which is actively involved in muscle 
development during embryonal stage [119, 265]. Wnt signalling is a 
pathway crucially involved in development of tissue and also in cell fate, 
proliferation, migration, polarity and death [68]. Deregulation of Wnt 
signalling facilitates cell transformation, tumour invasion and metastasis 
[59, 249]. 
When Wnt signalling is off, β-catenin is degraded by a degradation 
complex comprising CK1-α, GSK3β, Axin and APC protein. This 
degradation complex causes β-catenin phosphorylation, which in turn 
facilitates ubiquitination and proteasomal degradation [68]. When Wnt 
signalling is on, the signal cascade activates Dsh protein, which in turn 
enhances the phosphorylation of GSK3β in the cytoplasm and 
disassembles the degradation complex thereby rescuing β-catenin from 
degradation. β-catenin then shifts to the nucleus where it associates with 
TCF/LEF complex with sequence specificity promoting changes in 
transcriptional machinery that lead to activation of several downstream 
target genes [172].  
There are many downstream Wnt target genes, which play crucial 
roles in various cell processes like proliferation, survival and 
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differentiation. Targets include: MMP7, CD44, c-Myc, c-Jun, Cyclin D1, 
Slug and Cox etc. Deregulation of Cyclin D1 and c-myc can lead to cell 
transformation and cancer. We have undertaken this work to characterise 
Wnt/beta-catenin signalling in rhabdomyosarcoma (RMS) and to examine 
if it plays a role in pathogenesis of RMS. 
5.1 Does Wnt/ β-catenin signalling have a role in the pathogenesis of 
RMS? 
It is well known that Wnt signalling plays a central role in myogenic 
differentiation and cell proliferation [172, 265]. However, there is no 
convincing evidence to its relevance in the pathogenesis of RMS. 
Bouron-Dal Soglio et al. (2009) found no activating mutations of β-
catenin in their study and proposed that Wnt signalling may not be 
relevant in RMS [265]. Wnt2 overexpression was demonstrated in 
embryonal RMS cells derived from p53/c-fos double mutant mice by 
Singh et al. (Singh, 2010). They concluded that there might be a role for 
impaired Wnt signalling in embryonal RMS cells [63]. 
We undertook this study to characterise the role of Wnt/β-catenin 
signalling pathway in RMS and to see if this pathway had any relevance 
in the pathogenesis of RMS and whether this pathway could be targeted 
therapeutically in alveolar RMS where there are limited treatment 
options.  
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To see whether β-catenin is expressed in clinical samples of RMS, we 
did an immunohistochemical expressional analysis in 44 RMS cases. We 
constructed a TMA multiblock incorporating 34 cases and the rest were 
examined as full-face sections. Results indicated that β-catenin is 
expressed in around 60% of the cases, mainly in the 
cytoplasm/membrane. Those cases where there was a distinct perinuclear 
expression, we counted them as nuclear staining. Only 2/44 RMS cases, 
both embryonal RMS, showed nuclear expression of β-catenin, which is 
in agreement with the fact that there is no activating β-catenin mutation in 
RMS [265]. We did not find any statistically significant differences in the 
immunohistochemical expression of β-catenin in alveolar and embryonal 
RMS (64% vs. 56%). There also was no particular correlation between 
the expression of β-catenin with site, age or clinical outcome (data not 
shown). β-catenin expression also did not show any specific association 
when compared between the translocation-positive and negative alveolar 
RMS (5/7 vs. 4/7). 
In-vitro immunoblot experiments were designed next to see if the 
similar β-catenin expression could be elucidated in human RMS cell lines 
derived from alveolar and embryonal RMS. We not only found a high 
expression of β-catenin in all cell lines, but also other major structural 
and regulatory components of Wnt pathway. The cadherin family of 
proteins, which bind with β-catenin at cell membranes, was also present 
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in all cases. With the help of dosage and time-course immunoblot 
analyses, we showed that upon activation of the Wnt signalling pathway 
by its natural agonist, human recombinant Wnt3a, β-catenin could be 
stabilized and rescued from proteasomal degradation. This was 
comprehensively shown by the change in the phosphorylation status of β-
catenin before and after application of Wnt3a to the RMS cell lines. 
Changes in β-catenin phosphorylation were also mirrored in our 
immunofluorescence experiments where we could also demonstrate a 
time-dependent redistribution of β-catenin from the membranes to the 
perinuclear/nuclear region [172].  
PI3K/Akt pathway is a point of convergence of many signalling 
pathways (including EGFR, insulin, insulin-like growth factor etc.) that 
induce GSK-3β inactivation of by Ser9 phosphorylation. Since Akt and 
phospho-Akt remained unchanged after Wnt3a-mediated Wnt activation, 
it appeared that GSK-3β inactivation (by Ser9-phosphorylation) was 
independent of PI3K/Akt pathway. However, it was expected that Wnt3a 
activation would mediate GSK-3β inactivation by Ser9-phosphorylation; 
however, we saw a decrease in the levels of phospho-GSK-3β levels after 
Wnt3a stimulation (Figures 2c and d). This unveils the complexity of the 
regulation of central regulatory proteins at multiple levels by different 
effectors. Thus, there are likely to alternative mechanisms for GSK-3β 
inactivation following Wnt stimulation. One possible explanation could 
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be physical sequestration of GSK-3β by Disheveled, rather than 
inhibitory Ser9 phosphorylation, as shown by Aschenbach et al. in rat 
skeletal muscle [266]. In another study, Rao et al. (2008) suggested that 
interaction of β-catenin and APC does not need GSK-3β phosphorylation 
at Ser9 [267]. 
By using nuclear and cytoplasmic cell extracts, we also showed that 
there was an increase in nuclear β-catenin fraction and a concomitant 
decrease in the cytosolic fraction after Wnt3a-mediated activation of Wnt 
signalling. Further, using specific phopho-antibodies we showed that 
nuclear β-catenin was phosphorylated at Ser552, phosphorylation that 
promotes nuclear import once β-catenin is rescued from degradation.  
There also was a simultaneous decrease in the level of phospho-
S33S37T41-β-catenin in the cytoplasm of both cell lines after Wnt3a 
stimulation. These results were supported by similar findings on 
immunofluorescence experiments. 
Once it was established that β-catenin was stabilised and translocated 
to the nucleus, next we asked whether the nuclear β-catenin was 
functionally active. To test this, we employed a Wnt-specific luciferase 
based reported gene assay. We also looked at the expression pattern of 
downstream Wnt targets. Axin-2 is widely considered to be a specific 
Wnt target gene that is also a feedback inhibitor of the pathway. 
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We found a seven-fold increase in the transcriptional activity of the 
TOP flash reporter gene as compared to the FOP flash negative control 
after Wnt3a activation of RMS cells. Immunoblot assay was performed to 
look at the expression of Axin-2 after Wnt3a activation. Results indicated 
an increased expression of Axin-2 in both RMS cell lines. Previously, 
Lustig et al. (2002) have shown that Axin-2 is a feedback inhibitor of the 
Wnt pathway and limits it after activation [201]. Thus, our results 
indicate that transient Wnt signalling activation may be sufficient to 
redistribute β-catenin to the nucleus to induce TCF/LEF transactivation 
resulting in activation of its downstream targets. 
5.2 Could Wnt/ β-catenin signalling be a potential therapeutic target 
for RMS?  
Given the role of Wnt signalling in the various cell processes including 
cell growth, proliferation and survival, we now wanted to see the impact 
of Wnt signalling activation on cell proliferation in RMS cell lines. Upon 
Wnt3a-mediated Wnt signalling activation (over 72hrs), we found a 20% 
fall in the proliferation rate of alveolar, but not embryonal RMS cell 
lines. Two independent researchers in different labs who did not know 
the previous results confirmed the results. It was clear that Wnt signalling 
activation somehow retards cell proliferation alveolar RMS cell lines. To 
elucidate the mechanism underpinning this effect, we did apoptosis and 
cell differentiation assays. None of the RMS cell lines showed any 
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appreciable increase in apoptosis after Wnt3a activation. However, Wnt 
signalling activation was able to induce myodifferentiation in both 
alveolar and embryonal RMS cell lines. This was inferred from an 
increased expression of specific early muscle differentiation markers such 
as Myogenin, MyoD1 and Myf5, highlighting that Wnt signalling may 
reduce the proliferative ability of alveolar RMS cell lines by in promoting 
myogenic differentiation in RMS [266]. 
It remains unclear as to why even after the Wnt3a-induced expression 
of early myogenic differentiation markers, there was no significant 
reduction in the proliferative potential of embryonal RMS cells. It is 
possible that alveolar RMS, driven by Pax–FKHR fusion gene protein, 
could be inhibited by activation of Wnt signalling, at least in a subset of 
alveolar RMS cases. It is also possible that there may be other 
genetic/epigenetic mechanisms that may uncouple proliferation and 
differentiation in embryonal RMS cells. Further research is needed to 
understand these mechanisms. 
Our results indicate that activation of Wnt/β-catenin pathway may 
provide a therapeutic tool in treating alveolar RMS patients as it promotes 
myogenic differentiation and retards cell proliferation. In many ways, 
activation of Wnt signalling, which regulates a myriad of cellular 
functions is much easier than trying to inhibit it without having 
significant side effects, since it is also required for renewal for stem cells. 
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Lithium chloride, an FDA-approved drug used for bipolar mania patients, 
could have a potential role in the treatment of a subset of RMS patients as 
it inhibits GSK-3β and activates Wnt signaling [209]. There are many 
new Wnt agonists that are safe for patient use and could be used for 
clinical trials [64].  
To conclude, Wnt proteins are expressed in tissue samples and in the 
human RMS cell lines. It appears that this pathway is present in a 
repressed state in RMS and can be activated to provide a therapeutic 
target. Wnt signalling is relevant in the pathogenesis of alveolar RMS and 
we believe that it may have a tumour-suppressive role in RMS. There is 
potential to modulate the Wnt signalling pathway thereby providing 
additional therapeutic targets in alveolar RMS patients who, currently 
have a poor clinical outcome and limited treatment options. 
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6.1 Wnt activators as therapeutic option 
Our results indicate that Wnt signalling may have a tumour suppressor role in at 
least a subset of alveolar RMS. We have shown in-vitro that activation of Wnt 
signalling pathway using natural Wnt agonists can stimulate muscle 
differentiation and decrease proliferation rates in alveolar RMS cell lines. Thus, 
it might be expected that FDA-approved drugs like Lithium Chloride (LiCl) 
could be safely used in clinical trials and could have a therapeutic use in the 
treatment of alveolar RMS [268]. Since Wnt signalling is vital for many cellular 
processes including stem cell regulation, it can be envisaged that activation of a 
repressed Wnt pathway using Wnt agonists would be much easier than 
inhibition of a deregulated Wnt pathways (e.g. colorectal carcinoma).  
1. LiCl is a drug used in the treatment of bipolar maniac illness and has the 
potential to be used in therapeutic Clinical Trials for alveolar RMS, as it 
inhibits GSK3β and activates the Wnt signalling pathway [269].  
2. Bromoindirubin-30-Oxime (6-BIO), is another inhibitor of GSK3β, that 
is neuroprotective in Alzheimer’s disease and has the potential as a 
potential therapeutic agent in alveolar RMS [270].  
3. Valproic acid and Staurosporine are other drugs that can be used to 
activate Wnt signalling by targeting GSK3β. 
4. Simvastatin synergises with Wnt signalling both in vivo and in vitro 
[268]. 
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5. Curcumin is an agonist of Wnt signalling pathway and is neuroprotective 
for brain. Possible mechanisms of curcumin action are thought to be 
activation of Wnt antagonists like Wif-1, Dickkopf and GSK3β [271].  
Thus, using a range of safe, approved drugs one could target the Wnt signalling 
pathway to activate muscle differentiation in a subset of ARMS which may 
provide alternative therapeutic options.  
 
6.2 Animal experiments in athymic nude mice with/without control to see if 
Wnt agonists rescue the cohort with Wnt3a activation?  
We also plan to take this further into in-vivo experiments whereby we will 
administer Wnt agonists and placebo respectively to test and control athymic 
nude mice after inoculating them with RMS cells to investigate any differential 
pathological effects of Wnt signalling pathway on tumour characteristics – size, 
degree of differentiation, number of mitoses and apoptosis and micro-vessel 
density etc. We may expand this further to include experiments on control and 
transgenic Wnt -/- mice. 
 
 
 
 
 
 155 
6.3 To see the effect of miR-28 as the master switch regulating the Wnt/β-
catenin signalling in RMS. 
To further characterise the role of Wnt in muscle differentiation in RMS, we are 
investigating if any in-vitro interaction exists between Wnt signalling pathway 
and other muscle repressor proteins (like Id family) upon activation by Wnt3a.  
 Inhibitor of DNA binding proteins (Id) is a family of basic helix-loop-
helix (bHLH) transcription factors that regulate differentiation [272]. Id gene 
family (Id1-4) recognised in humans, and the proteins they encode share 
homology primarily in their HLH domain. They negatively regulate 
differentiation by forming inactive heterodimers with other bHLH proteins, and 
their basic domain binds to a DNA sequence element, the E-box, activating 
transcription. E proteins normally from hetero dimers with tissue restricted 
bHLH proteins such as MyoD1, NeuroD, etc. and forms active transcription 
complexes. Thus, Id negatively regulates differentiation by sequestering E-
proteins [272]. Wnt signalling has been shown to induce Id3, which in turn 
stimulates myoblastic differentiation [273]. In addition, Id-1 inhibits the 
transcription of both p53 and PTEN to activate the Akt pathway that 
phosphorylates GSK-3β (at Se9) and stimulates Wnt signalling [274]. 
           Recently, Macquarrie et al. (2012) have shown that both replicating 
myoblasts and RMS cells express MyoD. However, unlike myoblasts, the RMS 
cells cannot transit from the growth phase into terminal differentiation phase 
because they cannot dimerise with E-protein. If E-protein dimerization is forced 
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in the RMS cells (by RUNX1 and ZNF238), myodifferentiation could be 
achieved. miR-206, is thought to act like a ‘genetic switch’ that controls the 
transition from growth to differentiation [275].  
 Since Wnt3a-mediated activation of Wnt signaling path increases myo-
differentiation in RMS cell lines by increasing muscle specific differentiation 
markers including MyoD1 [248], a known E-box interacting bHLH protein, we 
would like to investigate whether an upstream interaction between Wnt 
signaling and Id (Id1-4) exists in RMS cells. If it does, we will look in to 
whether this ‘Wnt switch’ is mediated by miR-206. This will enable us to 
understand better how muscle differentiation is regulated in RMS so that better 
targeted therapeutic strategies could be developed. 
6.4 Final Conclusion  
Rhabdomyosarcoma (RMS) remains one of the most challenging tumours in 
paediatric oncology, accounting for around 5% of all malignant paediatric 
tumours [7-9, 276]. Of the two major subtypes of RMS, embryonal and 
alveolar, the latter portends a poorer clinical outcome [9].  
Canonical Wnt signalling pathway is an important evolutionarily 
conserved signalling pathway that is required for muscle development and 
embryonal somite patterning [118, 265]. β-catenin is a potent nuclear 
transcriptional activator and is the central effector of the canonical Wnt 
signalling pathway. Interestingly, constitutional activation of Wnt signalling 
also promotes tissue invasion and metastasis in various tumours [69].  
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We have shown that key regulatory proteins of the Wnt signalling 
pathway are expressed and are functional in rhabdomyosarcoma. β-catenin, the 
central regulatory protein of Wnt signaling pathway was expressed in over half 
of the RMS samples examined by IHC (n=44). Beta-catenin was also up- 
regulated in the human RMS cell lines derived from alveolar (Rh4, Rh30) and 
embryonal (RD, RD18) subtypes in-vitro after activation by its natural ligand, 
human recombinant Wnt3a (200ng/ml) [248].  
Following Wnt3a activation, we showed that beta-catenin was rescued 
from degradation, accumulated in the cytoplasm (active form) and translocated 
into the nucleus where it transactivated TCF/LEF to activate downstream targets 
like Axin 2. TCF/LEF nuclear transcription was confirmed by TOP/FOP Flash 
reporter gene assay, which showed 7-fold increase in activity following Wnt3a 
stimulation [248]. Furthermore, we demonstrated that activation of Wnt 
signaling decreased the proliferation rate of RMS cells by increasing myo-
differentiation. This was shown by increased expression of MyoD1, Myf5 and 
Myogenin in RMS cells by western blot experiments following Wnt3a 
stimulation [248]. Thus, we believe that Wnt signaling may confer tumour 
suppressive activity in RMS and is a therapeutic target in a subset of ARMS 
cases. 
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